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Summary 
The reverse vaccinology approach to the human cytomegalovirus (HCMV) genome, one of the 
largest known mammalian viral genome with a coding potential of more than 166 proteins, led to 
the identification of 94 potential membrane-associated or secreted proteins. Many of the selected 
proteins have no assigned functions but share a high degree of conservation among different strains. 
These designed ORFs have been synthesized as eukaryotic codon-optimized sequences in frame 
with both hexa-histidine tail and c-myc tag coding elements. A more detailed analysis was 
performed on a certain number of these tagged proteins in both epithelial and fibroblast human 
derived cell lines, natural targets of HCMV. As starting point 12 hCMV proteins with antigenic 
properties were chosen for further characterization in terms of structural and functional features.   
This work was aimed to the identification and functional characterization of two new HCMV 
surface exposed glycoproteins. 
The study is divided in two parts: first the identification and characterization of ORFX*; second the 
identification and characterization of a novel HCMV Fcγ binding protein. Regarding the first part, 
we focused our attention on ORFX gene product, a putative ORF identified by in silico analysis. 
Biochemical analysis on both ORFX viral protein product or transient expressed  single gene 
allowed us to conclude that ORFX is: a) heavily glycosylated protein; b) expressed as late product 
during infection; c) present in the assembly complex, the cellular site of virus assembly; d) present 
on the HCMV virion envelope and e) secreted in transient expression as by in silico prediction. 
These observations led us to search for ORFX partners among other HCMV envelope exposed 
glycoproteins. We found that gH was efficiently transported to plasma membrane only when co-
expressed with ORFX. Moreover, co-expression of  gH (and gH/gL) with ORFX and co-
immunoprecipitation experiments, carried on both transfected and infected cells, showed that 
ORFX is part of a gH-based complex. These results suggest that ORFX could function as both gH 
“escort” protein but also be part of a cellular recognizing complex and invite to a deeper analysis of 
both its functions and immunological properties. 
Regarding the second part of the study, we were able to identify two novels Fcγ binding protein 
coded by CMV: RL12 and RL13. The latter was also further characterized as recombinant protein 
in terms of cellular localization, Fc binding site and IgG internalization ability. 
*Names and protein sequences are, actually, under revision of NVD Intellectual property office 
 
 
 
 
Riassunto 
 
L’approccio di Reverse vaccinology applicato all’intero genoma del cytomegalovirus umano 
(HCMV), uno dei genomi più estesi all’interno della famiglia degli herpesviruses umani, ha portato 
all’identificazione di 94 ORF predette come codificanti per proteine di membrana o proteine 
secrete. La gran parte delle ORF selezionate non ha alcuna funzione assegnata pur rimanendo 
altamente conservata in tutti i ceppi conosciuti di HCMV. Tali ORF sono state inserite in vettori 
d’espressione eucariotici aggiungendovi una porzione C-terminale codificante per i tags His e myc. 
L’ analisi dettagliata riguardante le proprietà antigeniche dei prodotti proteici derivanti dalla 
trasfezione in cellule epiteliali e fibroblasti umane dei plasmidi in questione ha prodotto la selezione 
di 12 proteine virali.   
Questo lavoro di tesi è stato incentrato sull’ identificazione e caratterizzazione funzionale di due 
nuove glicoproteine presenti sulla membrana esterna di HCMV. 
Lo studio è diviso in due parti: in prima analisi, l’identificazione e la caratterizzazione di ORFX*; 
in seconda analisi l’identificazione e caratterizzazione di RL13 come Fc binding protein.  
Riguardo la prima parte del lavoro, l’attenzione è stata focalizzata sul prodotto genico di ORFX 
inzialmente identificata solo attraverso analisi in silico. Analisi biochimiche su ORFX prodotta in 
infezione e talvolta in trasfezione di cellule umane hanno portato i seguenti risultati: 1) ORFX è una 
proteina estesamente glicosilata 2) Vene prodotta nelle fasi tardive di espressione lungo il ciclo di 
replicazione virale, 3) è presente nel sito di assemblaggio virale (Assembly complex) in cellule 
infettate da HCMV, 3) è esposta sulla sua membrana esterna del virus,4) Viene secreta dalle cellule 
che la esprimono in maniera transiente come da predizioni. Queste osservazioni ci hanno guidato 
verso l’idea di cercare dei possibili partner proteici tra quelli conosciuti come presenti sull’envelope 
esterno virale. A tal proposito abbiamo riscontrato che gH veniva trasportato nella membrana 
plasmatica cellulare solo quando co-espressa con ORFX e viceversa. La Co-immunoprecipitazione 
di ORFX e gH da lisati di   cellule infettate e trasfettate con i singoli geni ha rivelato la diretta 
interazione tra le due proteine identificando ORFX come parte di un complesso “gH based”. Questi 
risultati delineano un ipotetica funzione di ORFX come proteina potenzialmente implicata nell’ 
“escort” di gH e talvolta parte di un complesso virale possibilmente riconosciuto dall’host. 
Riguardo la seconda parte del lavoro di tesi, i risultati sono riguardanti l’identificazione due nuove 
“Fc binding proteins” codificate da HCMV :RL 12 e RL13. Quest’ultima è stata sottoposta a 
caratterizzazione biochimica nella sua forma ricombinante in termini di localizzazione 
intracellulare, studio del sito di legame per le Fc e abilità della proteina a promuovere 
l’internalizzazione cellulare delle IgG nel contesto dei meccanismi virali di immuno-evasione.  
*Nomi e sequenze proteiche sono attualmente sotto la revisione dell’ufficio brevetti NVD 
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INTRODUCTION 
1. Human Cytomegalovirus  pathogenesis 
Human Cytomegalovirus (HCMV) is a member of the β-herpesviridae family that includes the 
herpesviruses of mammals, birds and reptiles [1]. Human Cytomegalovirus (HCMV) is ubiquitous, 
infecting as many as 85% of human adults. HCMV establishes latency and persists, replicating even 
in the face of robust host immunity through effects of numerous immune evasion strategies 
(reviewed in [1]). HCMV infections are normally relatively benign, but immunocompromised 
individuals can experience severe disease. Infants infected in utero can be born with disseminated 
HCMV disease or be damaged in terms of neurologic development (reviewed in [2]). Among the 
cell types infected are placental trophoblasts, which spread virus from mother to baby, and neurons 
and glial cells in the developing nervous system. Transplant patients do not control HCMV well and 
experience infection in gut epithelial cells, liver hepatocytes, monocyte-macrophages that 
disseminate virus to endothelial cells and smooth muscle cells which can accelerate transplant 
rejection [1]. HCMV is also a major opportunistic pathogen in AIDS patients, frequently infecting 
retinal epithelial cells and causing blindness. Nevertheless complete clearance of the virus by the 
organism is never achieved and lifelong lasting latency with recurrent and spontaneous viral 
reactivation is always observed. Thus in the presence of an impaired or absent immune system, 
antiviral therapies are necessary to counteract the severe disease associated to the HCMV primary 
infection or reactivation. However almost all the antiviral agents actually on the market showed a 
significant number of potential side effects including marrow and organ toxicity and increasing 
drug resistant viral strains [1]. Passive immunization using hyperimmune globulin preparations with 
high levels of antibodies against HCMV (CMVIG) are usually implemented as prophylactic tools to 
reduce the morbidity and mortality associated to HCMV infection in immunocompromised patients. 
For example combination of antiviral drug glancicovir and CMVIG proved to be effective in 
preventing HCMV infection in patients undergoing solid organ transplant [29]. Moreover a study 
suggests their effectiveness in the treatment and prevention of severe diseases associated to 
congenital HCMV infection [30]. Nevertheless, rather than a general prophylactic tool, the efficacy 
and effectiveness of CMVIG in reducing HCMV infection seems to be restricted to specific clinical 
cases while only modest beneficial effects were shown upon CMVIG treatment in other settings 
such as hematopoietic cell transplantation (HCT) and blood transfusion in premature newborns 
[31]. Additionally CMVIGs exhibit low potency in vitro [32] and must be administrated at high 
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doses to reach the amount of neutralizing antibodies required to exert a beneficial effect. To 
increase the efficacy of a passive immunization therapy, a series of neutralizing monoclonal 
antibodies against immunodominant HCMV envelope glycoproteins were developed. For example, 
a highly in vitro neutralizing antibody against gH was isolated from the spleen of a CMV 
seropositive patient. The monoclonal antibody, named MSL-109 or sevirumab, was tested in phase 
II clinical trials as treatment for CMV-induced retinitis in AIDS patients [33]. Unfortunately the 
tests were stopped due to lack of efficacy [34]. 
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2. HCMV structure and genome organization 
Human Cytomegalovirus is a β-herpesvirus. Although more recently validated by genome 
sequences, historically the members of the family were classified on the basis of the virion 
structure, composed of an envelope, tegument, capsid and an inner core containing the viral 
genome. The virus envelope is composed of a double host cell-derived lipid layer and contains the 
viral glycoproteins necessary for the cellular tropism. Compared to the other members of the family, 
the envelope is very irregular and generates a viral shape whose diameter reaches up to 300 nm with 
an average size of 230 nm diameter. Under the envelope is present an amorphous matrix referred as 
tegument. This compartment carries the majority of the HCMV expressed proteins plus a huge 
number of host species including proteins and nucleic acids. Several crucial viral functions are 
incorporated in the tegument including kinases, trans-activating factors and the most abundant and 
immunogenic protein pp65. The HCMV capsid is embedded in the tegument. The core of the capsid 
contains a tightly packed linear double stranded DNA genome. In line with the huge virus 
dimension, HCMV has the largest genome among its family with approximately 230 kb, 50% larger 
than HSV, despite the capsids of both viruses being roughly of the same size (110-125 nm) [1]. As 
for the other herpesviruses, genome organization reflects the common structure composed of unique 
long (UL) and unique short (US) genetic regions flanked by two sets of inverted repeats (RL, 
repeated long and RS, repeated short). Recombination phenomenon can occur among identical 
terminal and internal repeats, leading to genome isomerization. 
 
Fig. 1: A. Schematic representation of HCMV dissected virion B. Negative stained purified virion preparation analyzed 
through electron microscopy.  
 
Thus, genetic material isolated from a viral population consists of equal amounts of four 
different genomic isomers pooled together [2]. While the general genomic arrangement consistent of 
repeated and unique sequences is conserved among HCMV strains, a major difference in the open 
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reading frame (ORF) composition and organization can be observed among “laboratory strains” and 
“clinical isolates”. The latter are generally defined as viruses that underwent through none or 
limited passages in fibroblast cells before being clones as bacterial artificial chromosomes (BACs) 
and/or sequenced. On the contrary, laboratory strains indicate all the strains extensively passaged 
and adapted to growth in human fibroblasts. These latter have been selected for rapid replication, 
fast growing and high yields of produced virus. Consequently to the fibroblast adaptation severe 
genomic rearrangements occurred in these viruses. Both AD169 and Towne laboratory strains 
acquired a large deletion in a multilocus of the UL segment, concomitantly being replaced by 
duplicated RL region. An impaired tropism, tightly restricted to fibroblast cells only, resulted from 
the abrogation of several envelope glycoproteins encoded in the deleted segment. Due to these 
rearrangements, a difference in the coding potential can be observed between laboratory strains and 
clinical isolates. In particular, while the AD169, a laboratory strain prototype, is predicted to encode 
for 208 ORFs (including the repeated segments), the coding potential of a clinical isolate is 
estimated around 252 ORFs [3]. Recently, through an integrated approach that combines ribosome 
footprinting assays, high-resolution mass spectrometry and analysis of mutated viruses, Stern-
Ginossar and co-workers were able to identify a total of 751 translated ORFs including short 
peptides [4]. In spite of this huge coding potential, only a small subset of these proteins constitutes 
the mature virion: it has been estimated that around 50 [1,5] proteins are inserted in the virion, 
divided through the different compartments.  
 
 
Fig. 2: HCMV genome organization. ORFs map of conventional laboratory strain AD169 and clinical isolate. 
The AD169 genome (upper) carries TRL1-14 (green arrow), UL1-132 (dark blue arrow), IRL14-1 (green arrow), IRS1 
(red arrow), US1-36 (light blue arrow), and TRS1 (red arrow). In the clinical isolate RL1-14, (green arrow), UL1-151 
(dark blue arrow), IRS1 (red arrow), US1-36 (light blue arrow), and TRS1 (red arrow) are present. Modified from [3]. 
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3. HCMV Envelope glycoproteins  
The HCMV genome includes over 230 genes that encode 54 membrane proteins at least 25 
membrane glycoproteins found in the virion envelope [3–7].Being the modulator of viral entry, 
envelope glycoproteins play a key role in HCMV pathogenesis. Of the total number of proteins 
composing the virion, around 20 [1,5–7] were identified as envelope associated proteins. Notably, 
only 8 were demonstrated as essential for virus replication in vitro in different cell types: 
glycoproteins B (gB), M (gM), N (gN), L (gL), H (gH), UL128, UL130, UL131 [8]. All these 
proteins act as complexes on the viral surface. gB is an homotrimeric complex mediating virus 
attachment and fusion, involved in the first step of heparin sulfate proteoglycans (HSPG) tethering. 
The most abundant envelope glycoprotein, gM, forms an eterodimeric complex associating with gN 
that is present on the virion only as 1:10 ratio to gM. Like gB, gM:gN complex is involved in HSPG 
tethering and stabilization of virus-cell contact. The complex that has been involved in the fusion 
event is composed by the glycoprotein gH and gL. This complex is sufficient to mediate fibroblast 
infection while formation of a pentameric complex through additional binding of UL128, UL130 
and UL131 gene products is necessary for the infection of epithelial, endothelial, 
polymorphonuclear leukocyte and dendritic cells (DC). Indeed, the attenuated tropism observed in 
laboratory strains can be fully explained by the mutations of the UL128-UL131 locus [3,9,10].  
Various works describing the HCMV 
entry step suggest that the virus uses 
distinct cellular receptors, and 
consequently different entry pathways, 
depending on the target cell. HCMV 
entry consists of a first low specificity 
- high avidity tethering step of the cell 
surface HSPGs mediated by both gB 
and gM/gN [11,12]. The interaction 
with high avidity receptors has been 
shown to follow the first attachment 
step. A series of “post-attachment” receptors were proposed over the time, even if none of them 
completely fulfilled this role. The most accredited cellular interactors are β1 and, to a lesser extent, 
β3 integrins. Engagement of gB by these molecules induce receptors clustering and intracellular 
signaling. The entry step culminates with gH/gL mediating the fusion of viral and cellular 
membranes. While direct fusion at neutral pH has been observed in vitro in fibroblast cells [13], low 
pH dependent receptor-mediated endocytosis is required for viral entry in epithelial and endothelial 
 
Fig. 3: HCMV envelope glycoprotein complexes. The proposed 
role of each complex is indicated in the respective box. 
Modified from [11]. 
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cells [14–16]. Moreover, a recent report suggests that HCMV entry into DCs relies on 
macropinocytosis-like pathway in a cholesterol-dependent and pH-independent manner [17]. 
Interaction between gB and dendritic cell specific C-type lectin DC-SIGN (DC specific ICAM-
grabbing non-integrin) has been indicated to have a prominent role in DCs infection [18].  
3.1  gH/gL/gO and gH/gL/UL128-131  
HCMV gH/gL assembles with a third glycoprotein, gO,forming a disulfide linked trimer [26]. 
Studies of HCMV laboratory strain AD169 found gH/gL/gO in the virion envelope [26,27]. gO-null 
mutants produced small plaques in fibroblasts and titers <1000 lower than wild type HCMV 
[8,9,28,29]. A distinct HCMV gH/gL complex denoted gH/gL/UL128-131 is formed by the binding 
of three proteins UL128, UL130 and UL131. Recognition of the existence of gH/gL/UL128-131 
began with observations that HCMV laboratory strains, for example AD169 and Towne, were 
passaged many times in fibroblasts and no longer infected epithelial and endothelial cells and 
monocyte-macrophages. Sequencing of these lab HCMV showed that there were mutations in a 
block of 22 genes extending from UL128 to UL151 [5]. Repair of just the UL128, UL130 and 
UL131 genes in laboratory strains was sufficient to restore infection of epithelial and endothelial 
cells [30,31]. The UL128, UL130 and UL131 proteins were found to assemble onto gH/gL 
producing gH/gL/UL128-131 that was found in the virion envelope and mediated infection of 
epithelial and endothelial cells and monocyte-macrophages [32–34]. Assembly of all of gH, gL, 
UL128, UL130 and UL131 was necessary for a function complex; omitting any one protein 
produced a misfolded complex that was stalled in ER [35]. That gH/gL/UL128-131 was required 
for HCMV entry into cells,rather than some other step in virus replication, was demonstrated using 
PEG to overcome entry defects with 
HCMV UL128-131 mutants [36]. 
Combined with evidence that 
HCMV gO-mutants produced small 
plaques on fibroblasts these data 
suggested a model in which 
gH/gL/UL128-131 mediates entry 
into epithelial/endothelial cells and 
gH/gL/gO mediates entry into 
fibroblasts (Figure 4) 
Fig. 4: HCMV envelope glycoprotein complexes. The proposed model 
 of  trophism of each complex is indicated. 
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4. HCMV viral replication 
HCMV entry is followed by the delivery of both the tegument and DNA containing capsid into the 
cytoplasm. Tegument proteins with regulatory function dissociate from the capsid and remain in the 
cytoplasm or migrate independently in the nucleus, where they modulate cellular and viral genes 
expression. A thick layer of tegument proteins remains tightly associated with the capsid and 
contributes to the delivery of the DNA to the nucleus [19]. For the efficient delivery of HCMV 
DNA, an intact microtubular network (MT) is essential. The MT spans from cellular periphery up to 
the perinuclear MT organizing center (MTOC). HCMV moves along MT branches to reach the 
nuclear pore complex and to inject the DNA into the nucleus [19]. Viral replicative cycle starts 
shortly after with the expression of immediate early (IE) genes, that can be detected as short as 4 
hour post infection [20–22]. During the replicative cycle, genes expression can be divided in 
distinct temporal phases, defined as immediate early, early and late, that are linked together by a 
tightly regulated temporal cascade. A set of genes expressed with immediate early kinetic, whose 
transcription do not require de novo protein synthesis, act as global regulators of viral genes 
expression. Early genes protein products are responsible for DNA replication, while late genes 
encode for structural proteins and 
are transcribed following viral 
DNA replication [19]. 
 
Fig. 5: HCMV maturation. The model 
illustrates the HCMV virion particles 
formation, maturation and budding 
processes. Major cellular and viral 
proteins involved in these processes are 
reported (red and blue, respectively). List 
of abbreviations: DB, dense body; VP, 
virus particle; EE/RE, early 
endosome/recycling endosome; LE, late 
endosome; GB, Golgi body; ER, endoplasmic reticulum; NP, nuclear pore; INM, inner nuclear membrane; ONM, 
outer nuclear membrane; A, B and C, types of nuclear capsids. From [23] 
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5.  HCMV Immune response manipulation and evasion mechanisms 
Primary infection in immunocompetent individuals is accompanied by a period of viral 
dissemination (viremia). In this phase, virus excretion in bodily fluids, such as breast milk, blood, 
urine, saliva and seminal secretions lasts from months to years depending on the host age, and is the 
primary cause of viral transmission. Drop and clearance of the acute infection phase correlates with 
the mounting of strong humoral and, more importantly, cellular adaptive immune responses. 
Despite the setting up of a strong response, a complete clearance of infected cells is never observed. 
HCMV is able to establishing lifelong latency remaining silent in myeloid lineage cells [35].  To 
escape from the immune system surveillance, HCMV has developed a huge arsenal of genetic 
functions committed to alter and modulate both innate and adaptive arms of the immune response. 
In particular, HCMV coevolution within its host has led to the incorporation of a repertoire of 
functions with strong homologies to host genes. Thus the virus is able to subvert the immune 
system mimicking the same strategies and mechanisms used by hosts to clear the infection. 
Inhibition of complement cascade and natural killer (NK) cells activation, attenuation of interferon 
(INF) response and disruption of antigen presentation are only few examples of the functions 
hijacked by virus encoded chemokines, cytokine and cellular receptors homologues [35]. 
Table 1: List of selected protein functions encoded by cytomegalovirus that 
interfere with adaptive and innate immune response. Modified from [35]. 
Adaptive immune 
response 
Innate immune  
response 
Inhibits MHCI and II expression 
(US3) 
Fcγ Receptor Homologs              
(UL119, RL11) 
MHC I and II degradation           
(US2) 
Interferon-Mediated Immunity     
(IE2, UL83) 
MHC I degradation                     
(US11) 
Natural Killer Cells                         
(UL18, UL142, UL141, UL40) 
Binds MHC I molecules              
(US8, US10)  
Cytokine Homologs                     
(UL111) 
Inhibits TAP peptide transport    
(US6) 
Viral Chemokine Homologs    
(UL146, UL147, UL128-131) 
Inhibit MHC II expression         
(UL83) 
Apoptosis                                          
(UL36, UL37x1) 
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5.1 Fc receptors  
Fc receptors (FcR) are cellular surface exposed proteins present on almost every kind of immune 
cell and on some epithelial, endothelial and hepatocytic cells. Fc receptors are involved in the 
process of antigen recognition but, unlike the B and T cell receptors (BCR and TCR, respectively) 
they do not directly bind the antigen: instead the Fc receptor ligands are the constant region of 
immunoglobulins. Each Ig class has one or more dedicated Fc receptors and they are named 
according to the type of bound Ig: FcaR, FcγR, FcδR, FcµR and FcεR bind respectively Ig of the A, 
G, D, M and E class.   
The Fc receptors belong to the immunoglobulin superfamily (IgSF) and possess at least one 
immunoglobulin domain. The only exception is the FcεRII receptor that belongs to the lectin family 
and possesses a C-type Lectin Domain (CLTD). Two layers of β-sheets composed from seven to 
nine antiparallel β-strands connected by a loop compose the immunoglobulin fold common to all 
the members of the Ig superfamily [52].  
Fc receptor functions can be divided in three main categories: regulation of immune-cell responses 
through their activation or inhibition; antigen-antibodies immunocomplexes (IC) uptake; 
immunoglobulin transport and stabilization. 
Regulation of immune cells functions can be initiated through the recruitment of surface FcRs by 
antigen bound Igs. Depending on the kind of FcRs recruited and on the type of cell, activatory or 
inhibitory stimuli can be triggered. Many different downstream effects can result from the signaling 
cascade including up- or down- modulation of cellular proliferation, phagocytosis, degranulation, 
cytokine production. Most FcRs do not possess intrinsic signaling motifs thus they must associated 
with other proteins able to mediate the signals transduction. The Immunoreceptor Tyrosine-based 
Activatory or Inhibitory Motifs (ITAM and ITIM, respectively) are regulatory motifs that are 
present in the cytoplasmic tails of the receptor or in the associated units and regulate the signaling 
cascade. Receptor engagement induces a phosphorylation event on the tyrosine present in both 
motifs that culminates with the activation, in the case of ITAM triggered signaling, or in the 
inhibition, in the case of ITIM signaling, of the cell functions [52].  
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Another important function mediated by the FcRs is the immune complexes internalization. 
FcRs mediate ICs endocytosis and delivery into lysosomes for degradation. Proteolytically cleaved 
antigen-derived peptides can then be loaded and presented on MHC class I and II molecules [52].   
 
Fig. 6: Principal functions of Fc receptors. a: Fc receptors modulate positive or negative cellular signaling upon IC 
binding. Activation can lead to cellular proliferation, phagocytosis, degranulation and is mediated by the ITAM motif 
present in the FcR associated γ-chain. By contrast, an inhibitory signaling cascade can be initiated through engagement 
of the ITIM motif possessing FcγRIIB. b: FcR can mediate both IC and Ig-coated pathogens phagocytosis. The 
internalization process can lead to the clearance of the pathogen/IC and to MHC class I and class II antigen-presentation 
of the resulting antigenic peptides. From [52]. 
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5.2 Bacterial and Viral Fc receptor homologues  
Among the mechanisms used by pathogens to escape the immune system response, the 
acquisition of FcR homologues function seems to be highly diffuse. While the host cells use the 
FcR as a mean to sense and dispose of antibodies marked intruders, pathogens have developed 
similar functions in order to counteract immune system recognition. Staphylococcus aureus, a Gram 
positive bacterium, covers its membrane with the Fc binding protein A that captures and fixes 
immunoglobulins in the wrong orientation on the bacterium surface, disguising it and impairing its 
identification [55]. Fc binding proteins are highly conserved among the human herpesviruses: genes 
coding for FcR homologue functions were found almost in all genomes of the herpesviridae family 
suggesting a prominent role for these functions in pathogen survival [56]. 
Most of the viral FcRs (vFcR) recognize and bind the constant region of IgG probably 
impairing and inhibiting host effector function. Different mechanisms of action were proposed 
depending on the localization of the vFcR. Disguising mechanisms, similar to those observed for S. 
aureus protein A, can be put in place by vFcR present on the virions while circulating antibodies 
clearing can start from vFcR exposed on infected cells membrane. While the latter can inhibit the 
ADCC of the infected cells, the former can contribute to counteract the neutralization activity of 
antibodies bound to their target on the viral surface. The blockage of the free Fc portion can avoid 
the recognition of the viral particles and the activation of mechanisms such as the complement 
cascade or phagocytosis processes. This mechanism, named antibody bipolar bridging, has been 
described for Herpes Simplex Virus (HSV) heterodimeric FcR gE:gI.  
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Fig. 7: Herpesviral FcγRs mediated mechanism of protection against antiviral IgG. The Fc portion of human IgG 
bound to viral antigen on infected cell surface or on virus particle can recruit complement proteins (A) or host FcγRs 
(B). The former mechanism culminates with the complement-mediated lysis (ADCML) of the infected cells/viral 
particle. Recruitment of host FcγRs present on the surface of cytotoxic effector cells results in the antibody-dependent 
cellular cytotoxicity (ADCC). (C) Viral FcγR impairs both mechanisms through the blockage of the Fc portion of the 
IgG. This mechanism of antibody bipolar bridging protects the virus particle or infected cell from recognition and 
destruction. From [56]. 
Moreover, several reports underline the importance of the vFcγR endocytic activity of HSV, 
Pseudorabies Virus (PrV) and Varicella Zoster Virus (VZV) in the contest of the infected cells [57–
60]. For example gE:gI vFcγR complex in PrV infected monocytes internalizes antibodies-viral 
antigens complexes from the cell surface preventing the ADCML of the infected cell [61].  
HCMV is known to encode for two different FcγRs: glycoprotein gp68, encoded from the UL118-
119 locus, and gp34, encoded from the RL11 locus [62,63]. Both gp68 and gp34 are type I 
membrane proteins with a predicted IgSF domain and extensive glycosylation and localize on the 
membrane of transfected cells. gp68 is a 347 amino acid long protein generated through a splicing 
event between the UL119 and UL118 open reading frames (ORFs). It is predicted to possess up to 
12 potential N-linked and several O-linked glycosylations sites. In silico alignment showed that the 
IgSF domain of gp68 displays a high degree of similarity to the third IgSF domain of cellular 
FcγRI. Moreover an almost consensus ITIM motif (WSYKRL328) is present in gp68 cytoplasmic 
tail. Studies conducted on the purified ectodomain showed that gp68 binds Fcγ with a 2:1 
stoichiometry. Thus a single IgG can crosslink two molecules of gp68 allowing receptor 
clusterization in the absence of antigen binding. Surface plasmon resonance studies demonstrated a 
high affinity between gp68 and Fcγ with a KD in the nanomolar range. Furthermore the binding 
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remained stable at acidic pH, a major difference from the previous characterized gE:gI- Fcγ 
complex that dissociate at pH lower than neutrality [64].  
Less experimental information is available for RL11 gene product gp34. It consists of 234 amino 
acids and possesses only N-linked glycosylations on three predicted sites. Multiple alignments 
showed the presence of determinants that are conserved in the Fc binding region of host FcγIIIRs. 
The cytoplasmic tail contains a predicted dileucine internalization motif (DXXXLL226) that could 
indicate a propensity of the protein to enter the endocytic route upon Fcγ binding. Differential 
binding propensity to the IgG subclasses for gp68 and gp34 are still unknown, but the different 
reported affinities for IgG from various species suggest a diverse mechanism of binding for the two 
proteins. In particular, both gp68 and gp34 were able to bind to the same levels IgG1, IgG2, IgG3 
and IgG4 while only gp34 showed affinity for non-human IgG binding both rabbit and rat IgGs 
[62].  Moreover the HCMV FcRs seem to be diverse from HSV gE:gI not only for what concern pH 
requirement but also in terms of binding sites. In fact, while gE:gI binding site to the Fc fragment 
competes with protein A, HCMV vFcγRs bound to the Fc can be immunoprecipitated with the S. 
aureus Fc binding protein. Overall the structural and topological similarities between HCMV FcγR 
and the Fc binding proteins coded by other herpesviruses may indicate a mechanism of action 
similar for these classes of proteins [56]. Nevertheless some distinctive features can evidence a 
mode of action that do not reside in the mechanisms previously described, suggesting a diverse and 
peculiar role for the HCMV FcγR in the contest of viral infection.  
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1. Reverse vaccinology approach  
At the end of the 20th century, most of the vaccines that could be developed by traditional 
technologies had been developed, and new technologies were required to conquer the remaining 
pathogens. Remarkable progress was made during this period by the introduction of new 
technologies such as recombinant DNA and chemical conjugation of proteins to polysaccharides, as 
well as advances in the use of novel adjuvants. Additionally, a powerful tool came from the ability 
to access the genomes of microorganisms, a new technology that become available in 1995 when 
Craig Venter published the genome of the first free living organism (Fleischmann et al., 1995). This 
technological revolution allowed for the first time the capacity to move beyond the rules of Pasteur, 
using the computer to rationally design vaccines starting with information present in the genome, 
without the need to grow the specific microorganisms. This new approach was denominated 
“reverse vaccinology” (Rappuoli, 2000). More recently, the power of the genome has been 
complemented by the ability to interrogate the entire antigenic repertoire. This has been done by 
using libraries of expressed antigens and screening for the immunogenicity of the proteins (referred 
to as the “antigenome”) during infection (Giefing et al., 2008), or by testing directly for the 
presence and amount of antigens on the surface of bacteria. This latter technology takes advantage 
of the power of mass spectrometry to identify and quantify those antigens that are present on the 
bacterial surface (Rodríguez-Ortega et al., 2006). Surface proteins of gram-positive bacteria are first 
partially digested by treatment with proteases, and then the resulting peptides are loaded on a mass 
spectrometer that provides information on the identity and quantity of surface exposed proteins. In 
the case of the gram-negative bacteria, antigens on the surface are identified by mass spectrometry 
of membrane fragments free of cytoplasmic material that are released by gram-negative bacteria, 
which have been genetically modified to weaken the outer membrane stability (Berlanda Scorza et 
al., 2008). In addition to the discovery of many previously unknown antigens which have led to 
successful vaccine development in several instances, reverse vaccinology has made possible studies 
on antigen function, leading to an understanding of the biology of the pathogen. In conclusion, 
reverse vaccinology uses the entire protein repertoire of each pathogen to select the best candidate 
vaccine antigens. This allows the development of vaccines that were previously difficult or 
impossible to make and can lead to the discovery of unique antigens that may improve existing 
vaccines. Processes affecting vaccine development during reverse vaccinology are reported in 
Figure 8. 
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Figure 8. Schematic Diagram Summarizing the Pathway 
of Vaccine Development Starting from 
Reverse Vaccinology 
(1) First, computer analysis of the whole genome identifies 
the genes coding for predicted antigens and eliminates 
antigens with homologies to human proteins. (2) Then the 
identified antigens are screened for expression by the 
pathogen and for immunogenicity during infection. (3) The 
selected antigens are then used to immunize animals and test 
whether immunization induces a protective response. (4) 
Protective antigens are then tested for their presence and 
conservation in a collection of strains representative of the 
species (molecular epidemiology). (5) Finally, selected 
antigens are manufactured in large scale for clinical trials, 
and candidate vaccines are tested for safety and protective 
immunity in humans using established correlates of 
protection or efficacy studies. (6) Scientific, clinical, and 
technical information is then analyzed and approved by 
regulatory agencies, such as the Food and Drug 
Administration (FDA) or the European Medicinal Agency 
(EMA). (7) Policy-making bodies, such as the ACIP and 
equivalent bodies from other nations, make the 
recommendation on how the vaccine should be used. (8) The 
approved vaccine is then commercialized and used in large 
scale. At this point, phase IV clinical studies confirm 
safety. (from Reverse Vaccinology: Developing Vaccines in 
the Era of Genomics,2010 R.Rappuoli) 
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OUTLINE OF THESIS 
 
The reverse vaccinology approach to the human cytomegalovirus (HCMV) genome, one of the 
largest known mammalian viral genome with a coding potential of more than 166 proteins, led 
to the identification of 94 potential membrane-associated or secreted proteins. Many of the 
selected proteins have no assigned functions but share a high degree of conservation among 
different strains. These designed ORFs have been synthesized as eukaryotic codon-optimized 
sequences in frame with both hexa-histidine tail and c-myc tag coding elements. A more 
detailed analysis was performed on a certain number of these tagged proteins in both epithelial 
and fibroblast human derived cell lines, natural targets of HCMV. As starting point 12 hCMV 
proteins with antigenic properties were chosen for further characterization in terms of structural 
and functional features.  
This work was aimed to the identification and functional characterization of two new HCMV 
surface exposed glycoproteins. 
The study is divided in two parts: first the identification and characterization of ORFX; second 
the identification and characterization of a novel HCMV Fcγ binding protein. Regarding the 
first part, we focused our attention on ORFX gene product, a putative ORF identified by in 
silico analysis. Biochemical analysis on both ORFX viral protein product or transient expressed  
single gene allowed us to conclude that ORFX is: a) heavily glycosylated protein; b) expressed 
as late product during infection; c) present in the assembly complex, the cellular site of virus 
assembly; d) present on the HCMV virion envelope and e) secreted in transient expression as by 
in silico prediction. These observations led us to search for ORFX partners among other HCMV 
envelope exposed glycoproteins. We found that gH was efficiently transported to plasma 
membrane only when co-expressed with ORFX. Moreover, co-expression of  gH (and gH/gL) 
with ORFX and co-immunoprecipitation experiments, carried on both transfected and infected 
cells, showed that ORFX is part of a gH-based complex. These results suggest that ORFX could 
function as both gH “escort” protein but also be part of a cellular recognizing complex and 
invite to a deeper analysis of both its functions and immunological properties. 
Regarding the second part of the study, we were able to identify two novels Fcγ binding protein 
coded by CMV: RL12 and RL13. The latter was also further characterized as recombinant 
protein in terms of cellular localization, Fc binding site and IgG internalization ability. Finally 
binding specificity of both RL12 and RL13 seems to be confined to human IgG1 and IgG2.  
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ABSTRACT 
Human cytomegalovirus (HCMV) attachment and invasion of cells rely on the 
recognition of a still unknown cellular receptor with a viral envelope complex including 
gH. Recently it has been shown that, while gH/gL/gO complex appears to be important 
for HCMV entry into or spread between fibroblasts, formation of a pentameric complex 
including gH/gL, UL128, UL130 and UL131 is required for epithelial/endothelial 
tropism. Many HCMV-specific and conserved surface-exposed glycoproteins are 
required to be expressed in complexes for their correct final folding and function. 
In this study  we focused our attention on ORFX gene product, a putative ORF identified 
by in silico analysis. Biochemical analysis on both ORFX viral protein product or 
transient expressed  single gene allowed us to conclude that ORFX is: a) heavily 
glycosylated protein; b) expressed as late product during infection; c) present in the 
assembly complex, the cellular site of virus assembly; d) present on the HCMV virion 
envelope. These observations led us to search for ORFX partners among other HCMV 
envelope exposed glycoproteins. We found that gH was efficiently transported to plasma 
membrane only when co-expressed with ORFX. Moreover, co-expression of  gH (and 
gH/gL) with ORFX and co-immunoprecipitation experiments, carried on both transfected 
and infected cells, showed that ORFX is part of a gH-based complex. 
In summary, the protein product of the ORFX open reading frame represents a novel 
HCMV envelope glycoprotein and is found to be a direct gH interaction’s partner during 
the virus infection cycle. 
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INTRODUCTION 
 
HCMV is a ubiquitous betaherpesvirus infecting the majority of the world’s population. 
HCMV infection is usually asymptomatic in healthy individuals, but the viral infection 
causes severe disease in immunocompromised adults and birth defects in newborns. 
Infants infected in utero can be born with disseminated HCMV disease or be damaged in 
terms of neurologic development and transplant patients do not control HCMV well and 
experience infection in gut epithelial cells, liver hepatocytes, monocyte-macrophages that 
disseminate virus to endothelial cells and smooth muscle cells which can accelerate 
transplant rejection (1). 
The HCMV genome from clinical isolates includes over 230 genes that encode for ≈ 54 
membrane proteins at least 25 membrane glycoproteins found in the virion envelope(2). 
Recently, through an integrated approach combining ribosome footprinting assays, high-
resolution mass spectrometry and analysis of mutated viruses, Stern-Ginossar and 
colleagues were able to identify a total of 751 translated ORFs including short 
peptides(3). 
HCMV structural glycoproteins can be divided into two broad classes, those conserved 
between members of the family Herpesviridae (including gB, gH, gL, gM, and gN) and 
subgenus-specific glycoproteins without homology to other herpesviruses. These latter 
include, among others, gpRL13 (4, 5), gpTRL10(6), gpUL132(7), UL74 encoded gO(8), 
UL4-encoded gp48 (9), US27 (10), and UL33(11).  
Out of the total number of proteins composing the virion, around 20 were identified as 
envelope associated proteins(5, 12, 13). Notably, only 8 were demonstrated as essential 
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for virus replication in vitro in different cell types: glycoproteins B (gB), M (gM), N 
(gN), L (gL), H (gH), UL128, UL130, UL131 (14). Apart from the gB homotrimers, the 
HCMV most studied glycoproteins complexes include gH. The gH/gL/gO complex 
appears to be important for HCMV entry into fibroblasts as well as for cell-to-cell 
spreading among the culture (8, 15). The more recently discovered gH complex is the so 
called pentameric complex that include gH/gL, UL128, UL130 and UL131(16). The 
particular association of these five species on the viral envelope is required for 
epithelial/endothelial tropism (17). HCMV attachment begins with a low affinity 
tethering to the cell surface HSPGs, an event mediated by both gB and gM/gN(14, 18). 
Although there is a broad list of “post-attachment” receptors and none of them 
completely fulfilled the role, gH/gL complex has nevertheless essential to mediate the 
fusion of viral and cellular membranes. The presence of other associated species, and 
likely the pattern of receptor-like host molecules, determine the cell tropism and the 
mechanism of entry(19-22). Historically, gB has been the first target as antigen for a 
protective HCMV vaccine (23, 24). More recently, antibodies directed against pentameric 
complex appear to be a more robust tool in neutralizing HCMV infection(25). Although 
almost all subunit of the pentamer are target of specific antibodies, anti-gH antibodies 
represent the prevalent species accounting for neutralizing activity (26-28).  
 Many of the HCMV-specific glycoproteins, in contrast to the conserved glycoproteins, 
are not essential for in vitro replication in fibroblasts and presumably participate in cell 
and tissue tropism or pathogenicity (29). Structural glycoproteins that are not conserved 
between herpesviruses potentially add specific functions to individual genera or viruses 
and viral ligands that bind to cell surface receptors differ between the viruses and may 
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thus in part contribute to the differences in cell and tissue tropism. For example, Epstein-
Barr virus uses the two nonconserved glycoproteins gp350 and gp220 for initial 
interaction with the target cell(30). 
In the present study, we have approached the molecular characterization of HCMV-
specific ORFX. To this end, an HCMV (TR-derived BAC) recombinant with Flag 
epitope-tagged ORFX strain was generated. 
Our data reveal that the ORFX gene protein product is expressed with late kinetics. 
pORFX is highly glycosylated and localizes at the site of virus assembly and secondary 
envelopment in infected cells, forming part of the envelope of HCMV virion. These 
observations led us to search for ORFX partners among other HCMV envelope exposed 
glycoproteins. We found that gH was efficiently transported to plasma membrane only 
when co-expressed with ORFX. Moreover, co-expression of  gH (and gH/gL) with 
ORFX and co-immunoprecipitation experiments, carried on both transfected and infected 
cells, showed that ORFX interacts with gH during the viral replication cycle. 
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MATERIALS & METHODS 
Cell lines, plasmids and viruses. 
TR is a clinical HCMV strain that was derived from a ocular vitreous fluid sample from a 
patient with HIV disease (31) and was cloned into a BAC after limited passage in 
fibroblasts (32). 
HCMV strain TR and recombinant ORFX Flag-TR virus were propagated in human 
foreskin fibroblasts HFF-1 (ATCC: SCRC-1041) grown in minimal essential medium 
(Invitrogen) supplemented with 10% fetal calf serum, glutamine (100 mg/liter), and 
gentamicin (350 mg/liter). Virions were isolated by glycerol-tartrate gradient 
centrifugation as described (33). HEK293T cells were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal calf serum, glutamine and gentamicin. 
Lipofectamine 2000 (Invitrogen) was used to transfect HEK293T cells. Human codon-
optimized ORFX, gH(UL75), gL(UL115) and gB (UL55) HCMV genes based on the TR 
strain sequence were synthesized by Geneart and cloned in plasmid pcDNA3.1(-)/myc-
His C (Invitrogen) in frame with C-terminal myc and six histidine tag sequences. Single 
point-mutations were performed with the Quick Change Mutagenesis Kit (Stratagene)  
resulting in the mono-tag versions and the tag-less versions of these genes. 
Construction and generation of ORFX-Flag TR virus. Insertion of the Flag tag at the 
C-terminus of ORFX ORF on the TR BAC was achieved using the method of Two-step 
Red-mediated recombination as described in the short thecnical report (34). The primer 
pair used to amplify the kanamycin insertion cassette are the forward  5’-TTC GGC GCC 
AAC TGG CTC CTT ACC GTC ACA CTC TCA TCG TGC CGC AGA CTG ATT 
ACA AGG ATG ACG ACG ATA AG-3’ and the reverse 5’-TAT CAC CGG TCC AGG 
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TGA GAA AGA GAA GCC GCA ATC CGG GCG GCG GCA CA                           
TCA CTT ATC GTC GTC ATC CTT GTA ATC  AGT CTG CGG CAC GAT GAG 
CAA CCA AAT TAA ACCA ATT CTG ATT TAG-3’ where the underlined base pairs 
encode for the Flag peptide.  
Reconstitution of infectious virus. To reconstitute the virus, 2 ug of the BAC-HCMV 
DNA and 1 ug of the pp71 expression plasmid were transfected into MRC-5 cells by 
electroporation as described in the current protocols. Culture medium was changed 24 h 
later and the cells were split and cultured until the appearance of virus plaques.  
 The virus stock was prepared by harvesting cell-free culture supernatant when the entire 
monolayer of cells was lysed or the cells were split and cultured until the appearance of 
virus plaques.  
Purification of HCMV-TR virions. HCMV particles in cell supernatants were separated 
into virion, dense body, and noninfectious enveloped particle (NIEP) fractions by 
positive density/negative viscosity gradient centrifugation as described previously (35). 
Particle concentrations in the preparations were estimated by counting negatively stained 
samples by EM in relation to a standard concentration of latex beads. To separate virion 
envelope proteins from capsid and tegument proteins, 108 particles were mixed 1:1 with 
envelope stripping buffer (2% Nonidet-P40 in PBS) and incubated for 15 minutes at 4°C. 
Particles were pelleted (12,000 g for 5 minutes at 4°C), and the soluble envelope fraction 
was harvested. The insoluble capsid/tegument material was washed twice with envelope-
stripping buffer and once in PBS before being solubilized in SDS-PAGE sample buffer. 
Flow cytometry. For detection of membrane exposed ORFX, HEK293T transiently 
transfected with vectors coding for ORFX, gH, gB and empty vector were trypsin 
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detached 48 h post-transfection, incubated 30 min at RT with Live&Dead Agua 
(Invitrogen), diluted 1:400 in PBS then incubated with different dilutions of  anti-ORFX  
polyclonal mouse sera for 60 min on ice. As secondary antibody, Alexa Fluor 647-
conjugated goat anti-mouse was used for 30 min on ice at 1:200 dilution. A total of 10
4
 
cells were analyzed for each curve using FACSCanto II (Becton Dickinson, Heidelberg, 
Germany). Experiments were performed in triplicate for statistical consistency, means 
and standard deviations were analyzed and plotted using Graphpad Prism software.  
Glycosidase treatment. Samples were treated with PNGase F (P0705S; New England 
BioLabs) or ENDO H (P0703S; New England BioLabs) according to the manufacturer’s 
instructions. Briefly, the samples were denatured in glycoprotein-denaturing buffer at 
100°C for 10 minutes and cooled to 0°C for 5 minutes. The samples were then digested 
overnight at 37°C with PNGase F or ENDO H before being analyzed by Western 
immunoblotting. 
Immunogold electron microscopy. Purified virions were air-dried to the surface of 
Formvar-coated EM grids. The grids were treated with mouse Anti-Flag antibody 
(Sigma-F3165) for 4 hours at room temperature, washed 3 times with PBS, and incubated 
with goat anti-mouse antibody conjugated to 5-nm gold particles for 1 hour at room 
temperature. After further washing in PBS, the grids were negatively stained with 
phosphotungstic acid and subjected to EM. 
SDS-PAGE and immunoblotting. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 10 to 15% polyacrylamide gels 
under standard conditions. Proteins were transferred to nitrocellulose membranes, and 
membranes were blocked with PBS containing 0.1% Tween 20 and 5% powdered milk. 
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Antibodies and sera were diluted in PBS containing 0.1% Tween 20. For detection of 
primary antibody binding, horseradish peroxidase- conjugated anti-rabbit or anti-mouse 
immunoglobulin G antibody (Perkin Elmer) and the enhanced chemiluminescence 
detection system (Pierce) were used according to the manufacturer’s instructions.  
Immunofluorescence. Cells were plated on glass coverslips and infected with HCMV. 
At 7 days PI, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% NP-
40, pre-blocked with HCMV seronegative human IgG and incubated with primary 
antibody for 1 hour at RT°C. Following washing, secondary antibodies were incubated 
for 1 hour at 37°C, washed again, and mounted with DAPI Pro-long Safe Stain mounting 
media (Invitrogen). Primary antibodies were rabbit anti-Flag (F7425; Sigma), sheep anti-
human TGN46 (AHP500; Serotec), mouse MAb anti-pp28 (6502; Abcam), and mouse 
anti-gH (2470-5437; Adb Serotech). Secondary antibodies were Alexa Fluor 488-, 568-, 
and 647-conjugated goat anti-mouse and anti-rabbit (Invitrogen). The intracellular 
locations of antibody-tagged proteins were examined under laser illumination in a Zeiss 
LMS 700 confocal microscope, and images were captured using  ZEN 2009 software. 
Immunoprecipitations. HFF-1 cells were infected with wtTR and UL-116Flag-TR 
stocks. Protein expression was allowed to proceed for 72hrs before the cells were washed 
in 1xPBS (0.137M NaCl, 0.0027M KCl, 0.1M, Na2HPO4, 0.002M KH2PO4, pH7.4) and 
lysed (0.025M Tris, 0.15M NaCl, 0.001M EDTA, 1%NP-40, 5% glycerol, pH 7.4) in the 
presence of protease inhibitors. 500ug of protein was incubated with 5ug of MSL-109 
(courtesy of A.Feire) antibody for 16hrs at 4°C. Complexes were immunoprecipitated 
using the Protein G Dynalbeads (Invitrogen) according to the manufacturer’s protocol. 
The complexes were washed four times in lysis buffer. Samples were boiled for 5 mins at 
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100°C before immunoblotting. The same procedure described above was adopted for the 
immunoprecipitation experiments carried out on transiently expressing HEK293T cells. 
Complexes were captured in parallel experiments with covalently linked anti-His ab 
magnetic beads (Genescript) and anti-c-myc magnetic beads (Pierce) to avoid  
background signals in resulting eluted materials.  
RESULTS 
 
Primary structure of ORFX gene product  
In all sequenced HCMV genomes, the ORFX ORF is located in the unique-long (UL) 
region between the ORFY and ORFW genes on the antisense coding strand (figure 1A 
not shown under NVD IP department revision). The ORFX mRNA was previously 
shown to arise in the true-late stage of AD169 infection as part of the ORFY-ORFW 
transcription unit but no analysis were on the gene translation that remained a putative 
glycoprotein (36). A multi-alignment of ORFX translation primary sequences derived 
from gene sequences of HCMV clinical and lab adapted strains is shown in figure 1B. 
The conservation degree among most representative HCMV strains is 98% resulting in a 
very strong conservation of this protein among the cytomegalovirus population. The 
ORFX ORF is predicted to encode a 313 amino-acid glycoprotein comprising a signal-
peptide (1 to 24 amino acids,SP in figure 1B), a threonine-rich domain (27 to 157 amino 
acids) with 14 predicted N-linked glycosylation. The resulting polypeptide would have a 
molecular mass of 34.2 kDa without the contribution of the carbohydrate moiety and the 
absence of membrane anchor designates a secreted protein. 
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Kinetics of ORFX expression during HCMV replication.  
To investigate the expression kinetics of ORFX during productive HCMV infection we 
had to generated a recombinant HCMV (TR-derived BAC) with a Flag-tag fused to the 
ORFX C-terminal end (see materials and methods). The reconstituted TR ORFX-Flag 
was used to infect HFF-1 cells where the kinetic of pORFX expression was monitored by 
immunoblot using an anti-Flag antibody in cell extracts harvested at different time points 
ranging from 4 to 120 h p.i.. As control, expression of the major immediate protein IE1 
pp72 (UL123) and of the late pp28 (UL99) phosphoprotein were detected. Results are 
shown in figure 2A. In extracts of infected human fibroblasts, ORFX migrated as two 
species, a faster-migrating protein of 76 kDa and a slower migrating protein of about 125 
kDa. The latter appeared to be the mature product of the 76 kDa species as indicated by 
the accumulation of the intracellular products starting from 72 h p.i. through 120 h p.i. 
coincident with the expression kinetic of pp28 (37). At time points after infection when 
signals for pORFX were not observed, IE1 pp72 was present, as expected, already being 
expressed after 4 h p.i. and remaining for the duration of the HCMV replication cycle. 
Consistently with the observed kinetic pattern, a metabolic blockade with PAA resulted 
in the disappearance of the 125\76-kDa bands (Fig. 2B), indicating that the ORFX protein 
is expressed late during HCMV replication. Trafficking of herpesvirus glycoproteins to 
the Golgi apparatus is associated with the processing of N-linked oligosaccharides to 
complex oligosaccharides that are resistant to endo H (38). The high number of putative 
N-linked glycan sites (n = 14) present in pORFX, the difference between the apparent 
molecular mass (125 kDa) observed for this protein by immunoblotting and the 
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calculated molecular mass (34.2 kDa) of the 313- amino-acid polypeptide backbone 
suggested that pORFX undergoes an extensive post-translational glycosylation process. 
Indeed, digestion with endoH which removes only high-mannose carbohydrates and 
PNGase F, which removes all the complex and high-mannose N-linked sugars showed 
the faster migrating 76kDa band sensitive to endoH treatment  while the 125kDa band as 
PNGase F-sensible producing a band of approximately 35kDa in line with the expected 
molecular weight (Fig 2C). It appears that  a fraction of pORFX (125kDa)  produced in 
TR-HCMV-ORFXFlag-infected cells acquires substantial endo H resistance, consistent 
with all or most of the glycoproteins reaching the Golgi apparatus.   
 
Subcellular localization and colocalization of pORFX with tegument and envelope 
HCMV proteins. In order to investigate the localization of pORFX in HCMV-infected 
cells, the Flag tag of  the TR ORFX-Flag virus was employed to trace its subcellular 
distribution by confocal microscopy showing at 96 h p.i. a specific colocalization for the 
Trans-Golgi marker TGN 46 among a viral HFF-1 syncitia present at this time point (Fig 
4A). Based on the cytoplasmic compartmentalization of pORFX, we explored whether 
other structural HCMV proteins gathered at the pORFX-containing site. To this purpose, 
in HFF-1 TR-ORFX Flag infected cells following fixation at 72 h p.i. , antibodies against 
the tegument phosphoprotein pp28 and the envelope glycoprotein gL were employed. 
HCMV pp28 was previously reported to localize with other tegument and viral envelope 
proteins at the virus assembly complex (AC) site during the late phase of the infectious 
cycle (39, 40), and to be acquired by the virion in the cytoplasm. Interestingly, pORFX 
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colocalized with pp28 (Fig. 4B) and gL (Fig. 4C), consistent with its presence at the site 
of viral AC, thus suggesting its possible integration into the HCMV virion.  
 
pORFX is a component of the HCMV virion envelope. The finding that pORFX is a 
glycoprotein that localizes to the intracelluar virion assembly complex raised the 
hypotesis that it might be a virion surface envelope protein. With this rationale, we 
purified 
TR ORFX-Flag particles by negative-viscosity–positive-glycerol/tartrate gradient 
centrifugation then performed a detergent extraction to separate envelope and tegument 
fractions and analyzed them by immunoblotting  with the anti-Flag antibody. In this 
virion fractionation studies, ORFX protein copurified with glycoprotein B (UL55) and 
glycoprotein L (UL115)  in the soluble envelope fraction, rather than with pp65 (UL83) 
in the tegument. IE1 (pp72), a nonstructural protein present only in preparations of 
infected cells antibody was used as control of virion purity (Fig. 5A). The presence of 
pORFX on the virus envelope was supported by immunoelectron microscopy, in which 
5nm gold-labeled secondary antibody against the anti-Flag exhibited the labeling around 
the inner surface of the envelope (Fig 5B).  
pORFX co-immunoprecipitates with glycoprotein H in transient expressing HEK-
293T cells The pORFX viral envelope localization togheter with the intracellular staining 
showing the ORFX completely ER-retained in MRC-5 transient expression experiments 
(data not shown) suggested us the idea that it might be associated with one or more of the 
major reported HCMV envelope glycoproteins as showed in literature for the pentameric 
complex members(17).  
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To investigate this possibility  we performed a cytofluorimetric assay in which  HEK-
293T cells were co-transfected with a TR-ORFX encoding plasmid in binary 
combinations with different known trans-membrane HCMV glycoproteins. In particular  
we show the representative experiment runned with the couple ORFX/gH using gB as 
negative control of interaction. After a plasma-membrane staining of these cells with a 
polyclonal anti-ORFX mice sera at different dilutions, we used FACS analysis to 
measure the mean fluorescence intensity coming from the FITC conjugated secondary 
Ab. To clearly exclude possible aspecific binding coming from the single protein 
contributions we included the single transfectant populations as negative controls. 
Experiments were performed in triplicate to have a statistically consistent data set.  Mean 
fluorescence intensities  plotted in Fig. 6A with respective standard deviations show a 
strong ORFX plasma membrane signal only for the ORFX-gH co-expressing cells. This 
ORFX plasma membrane export event led us to consider the possibility  of a physical 
interaction between the two proteins since, in this configuration, at least a fraction of 
ORFX became exported from the ER.  
 To test the formation of a gH-ORFX complex, both proteins were immunoprecipitated 
from ORFX-his/gH-Myc transfected cell lysates in parallel and complementary 
experiments with anti-His and anti-Myc antibodies. Complexes were captured with 
magnetic beads covalently linked to the respective Abs; eluted material was separated by 
SDS-PAGE and analyzed by immunoblot using anti-tag antibodies (Fig. 6B). Both 
ORFX and  gH proteins were successfully co-immunoprecipitated from cell lysates 
meanwhile gB used as negative control was not captured by any of the two proteins as 
expected and shown in Fig 6B . 
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pORFX interacts with glycoprotein H in infected HFF-1 and colocalize with it in the 
intracellular AC. To further confirm the ORFX/gH interaction in our infection system 
we used the anti-gH human monoclonal  MSL-109 Ab to immunoprecipitate gH from 
TR-ORFX-Flag infected HFF-1 cell lysates at 96 h p.i. As negative control we used a 
wild-type TR infected HFF-1 cells lysate. Meanwhile as positive control we tested the 
eluted materials with an anti-glycoprotein L rabbit-polyclonal antibody since gL is 
known to be the gH direct interactor (17). The interaction between gH and ORFX was 
confirmed by the anti-Flag signal present in TR-ORFX Flag elution lane (Fig.7A). 
The direct association between pORFX and gH was then supported by a colocalization 
experiment carried out on TR-ORFX-Flag infected HFF-1 cells  using confocal laser 
scanning microscopy.  Confocal microscopy analysis of permeabilized TR-ORFX-Flag 
infected HFF-1 cells stained with both anti-gH mAb and anti-Flag mAb revealed a strong 
accumulation of ORFX on the viral Assembly Complex site that extensively overlapped 
with gH signals as shown also by cell orthogonal projections in Fig. 7B (yellow color in 
right merge panel). 
 These datas reflect the ORFX/gH association during the TR-HCMV replication cycle. 
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DISCUSSION 
Although a great deal is known about the envelope of betaherpesviruses, our 
understanding of the composition of the HCMV envelope is still incomplete. Growing 
numbers of viral glycoproteins have been reported to be components of the HCMV 
envelope, including molecules conserved between members of the Herpesviridae family 
(gB, gH, gL, gM, and gN) and others that are HCMV specific (57) (e.g., gO 
(8), gpTRL10 (6), gpRL13 (4, 5), UL4/gp48(9), gpUL128 (17), gpUL130 (41), gpUL132 
(7), US27 (42), and UL33 (11).  
It is reported that genus-specific envelope glycoproteins contribute to the broad 
cell/tissue tropism of HCMV and its pathogenicity.  
In this study, we have characterized the HCMV specific ORFX-encoded protein product 
in infected human fibroblasts, constructing a  ORFX-Flag tagged version of the BAC-
reconstituted strain TR. Early studies have identified the late 2.1-kb and 1.2-kb 
transcripts, rising from the UL119-UL115 transcriptional unit, to encode the viral 
mRNAs of ORFX and UL115 (i.e. gL) (36). Further experiments were carried out on a 
AD169 deletion mutant virus for ORFX gene that was reported to be produced at wild-
type levels by human fibroblasts indicating this gene as dispensable for HCMV growth in 
HF (43).  
During our study we found that pORFX is a PNGase F-sensitive glycoprotein,  
synthesized late during productive HCMV infection. In infected human fibroblasts, 
pORFX is targeted to the intracellular viron assembly complex site together with several 
HCMV tegument and envelope proteins. Consequently, we found that pORFX can be 
incorporated into purified TR virions being exposed on the viral envelope and showing 
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that it interacts with gH in human fibroblasts during the HCMV-TR viral replication 
cycle. Based on these results, we propose that pORFX constitutes a novel HCMV 
structural envelope glycoprotein.  Several studies have investigated antibody specificities 
against HCMV structural proteins in detail and recently the pentameric gH based 
complex (gH, gL, UL128, UL130, and UL131) has been reported to induce at least 45 
monoclonal antibodies (mAbs) in rabbits immunized with an experimental vaccine virus 
in which the expression of the pentameric gH complex was restored. Over one-half of the 
mAbs have shown neutralizing activity (25).  Because of its location in the virion 
envelope and molecular interaction with gH, pORFX is potentially capable of inducing 
neutralizing antibodies and thus could represent a target of the humoral immune response 
during natural infection. In addition, since induction of strain-specific antibodies and 
antigenic variation is a well-known phenomenon in HCMV biology proteins like ORFX, 
showing high degree of primary aminoacidic  secquence conservation among different 
lab and clinical strains (Fig 1B), could potentially represent an antigenic solution in this 
scenario. 
Moreover, the advances made in the attempt to understand HCMV entry led to the 
statement that gH/gL/UL128–131 is required for entry into epithelial and endothelial 
cells, but not for fibroblast entry where gH/gL/gO seems to be the main protagonist 
complex (16, 21, 44). However, the accepted hypothesis is that HCMV entry into 
fibroblasts could involve viral proteins other than gH/gL/UL128-UL131. In addition, is 
well assessed that gH and gL are essential for viral production in fibroblasts (29). By 
contrast, we wouldn’t  exclude, among all the different HCMV strains, the presence of 
alternative complexes formation that could help to the correct protein folding along the 
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secretory pathway or  give the virus different trophisms for diverse cellular targets . With 
this aim, given that ORFX is present at the viral envelope site, we investigated its 
possible HCMV envelope’s partners finding that the co-expression of ORFX and gH in 
transfected HEK 293T cells allowed the ORFX delivery on the cellular membrane (Fig), 
by contrast ORFX expressed alone remain ER retained (data not shown)  as for other 
HCMV glycoproteins such as gH, gL, gO, gM, and gN, which also require complex 
formation for proper folding and transport to the cell surface (45-47); later we found the 
ORFX physically interacts with gH during the TR replication cycle  in human fibroblasts. 
Unfortunately, we were not able to report datas showing the presence of the gH/ORFX 
complex on the viral envelope possibly due to the low abundance of this complex in 
relation to the well characterized gH/gL based complexes. However, our datas on the 
gH/ORFX complex, obtained from single particle analysis by electron microscopy, 
revealed ORFX sharing the same gH binding site usually adopted by gL. This data was 
confirmed by co-immunoprecipitation experiments done using lysates of HEK 293T cells 
co-expressing gH-myc,gL and ORFX-His in which the ORFX/gH complex was captured 
by anti-His tag antibodies; as result, the anti-gL immunoblotted eluted material showed 
complete absence of signal for the well known gH partner (data not shown).  
Speculations on this results could suggest that ORFX can function as both gH “escort” 
protein and eventually be part of a cellular recognizing complex in alternative to gL.  
Whether the gH/ORFX complex or the ORFX protein alone plays an essential role in the 
biology of HCMV remains to be determined; the maintenance of the ORFX ORF in the 
genome of clinical isolates strongly argues for an essential role in the replication of this 
virus in the natural host. A more complete study of the function of envelope 
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glycoproteins as ORFX whose expression is restricted to individual members of a virus 
group could provide insight into the role of these virion envelope components in specific 
aspects of infection, such as cell tropism and disease induction, which in turn define the 
unique phenotypes of individual herpesviruses. 
FIGURES 
Figure 1 A-B (under NVD Intellectual Property department revision) 
 
 
 
 
 
 
Fig. 2. Expression of the ORF X glycoprotein in HCMV-infected fibroblasts. (A) Uninfected (mock) 
and TR-ORF X-Flag-infected HFF-1cells at an MOI of 5 were harvested at the indicated times p.i. 
Equivalent  amounts of cell lysates were subjected to SDS-PAGE and analyzed by immunoblotting 
with antibodies reactive with Flag or the HCMV IE1 and pp28 proteins. Actin detection was used 
as a protein loading control. (B)Experiments were performed as described above for panel A to 
assess the effect of PAA treatment (PAA) on late-phase protein expression. (C) Whole-cell lysates 
of TR ORF X-Flag-infected HFF-1 cells (72 h p.i.) were left untreated or digested with EndoH and 
PNGase F. The preparations were subjected to immunoblot analysis using an anti-Flag antibody. 
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Fig. 3. Intracellular localization of ORF X in infected HFF-1 cells. Fibroblasts were infected with 
the recombinant virus TR-ORF X-Flag for 72 h. The intracellular localization of the individual 
proteins was determined by comparing the signal from anti-Flag-specific antibody (ORF X) with 
those of antibodies specific for HCMV envelope glycoprotein L, tegument protein pp28 and a 
component of the secretory pathway  trans-Golgi network [TGN46]. The merge panel shows 
colocalization of the signals, cell nuclei are also stained blue. 
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Fig. 4. Localization of ORF X on the virion envelope. (A)Western blot performed on purified 
virions from virus expressing a full-length ORF X with a C-terminal epitope Flag tag. 
Complete virions (V), envelope fraction (E), and tegument/capsid fraction (T) were probed 
for the antigens indicated .(B) Immunogold EM staining for anti-Flag mAb in purified TR-
ORF XFlag virions. Original magnification, ×40,000 
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Fig. 5. ORF X interaction with gH in HEK 293T transfected cells. (A) Binding of Anti-ORF X 
mouse sera to surface-exposed ORF X in presence of gH. HEK293T cells transfected with 
expression vectors for ORF X, gH and gB in different combinations were first stained at 
4°C with anti-ORF X polyclonal mouse sera at different dilutions. Excess of probe was 
removed by washing in PBS and then cells were fixed and stained with AlexaFluor-488 
conjugated anti-mouse antibody. 488-fluorescent positive cells were found only in the ORF 
X/gH co-transfection setup and compared to the single transfectants for ORF X,gH,gB and 
the couple gB/ORF X used as negative controls. (B) ORF X co-immunuprecipitation with 
gH. HEK 293T transiently expressing ORF X-his/gH-myc, ORF X-his, gB an ORF X-his/gB. 
Cell lysates were subjected to parallel immunoprecipitation experiments with both 
covalently linked magnetic anti-His and anti-myc beads . The respective eluted materials 
were separated by SDS-PAGE and togheter with the inputs analyzed by immunoblot for 
both the His and myc tag.  
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Fig. 6. ORF X interaction with gH in infected HFF-1 cells.(A) Co-immunoprecipitation (Co-IP) 
of the ORF X - gH  complex. Co-immunoprecipitation studies were carried out with lysates 
prepared from HFF-1 infected with HCMV-TR ORF X Flag and wt TR separately. Complexes 
were captured using the human monoclonal antibody MSL-109. Elutions and crude extracts 
were subjected to immunoblot using a rabbit anti-gH polyclonal sera, an anti-Flag M2 clone 
monoclonal mAb and for control purposes a polyclonal antibody specific for gL.  
(B)Intracellular co-localization between signals derived from anti-Flag mAb (red) and anti gH 
pAb (green) among all the z planes showed on the left merge panel with the respective 
orthogonal projections. 
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Fig S1. Multiple-step growth curve analysis of the reconstituted virus ORF X-Flag TR and of 
the parental HCMV strain TR. HFF cells seeded in six-well dishes (5 × 10
5
 cells/well) were 
infected with an MOI of 0.1. At the indicated time points (days post infection) supernatants 
from the infected cultures were harvested, and total PFU of infectious virus in the culture 
supernatants were determined by plaque assay on HFF cells. Time point 0 titers represent 
input inocula and each data point represents the average of three independent wells.  
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ABSTRACT 
The human cytomegalovirus (HCMV) protein RL13 has recently been described to be present 
in all primary isolates but rapidly mutated in culture adapted viruses. Although these data suggest a 
crucial role for this gene product in HCMV primary infection, no function has so far been assigned 
to this protein. Working with RL13 expressed in isolation in transfected human epithelial cells, we 
demonstrated that recombinant RL13 from the clinical HCMV isolates TR and Merlin have 
selective human immunoglobulin (Ig)-binding properties towards IgG1 and IgG2 subtypes. An 
additional Fc binding protein, RL12, was also identified as an IgG1 and IgG2 binding protein but 
not further characterized. The glycoprotein RL13 trafficked to the plasma membrane where it bound 
and internalized exogenous IgG or its constant fragment (Fcγ). Analysis of RL13 ectodomain 
mutants suggested that the RL13 Ig-like domain is responsible for the Fc binding activity. Ligand-
dependent internalization relied on a YxxL endocytic motif located in the C-terminal tail of RL13. 
Additionally, we showed that the tyrosine residue could be replaced by phenylalanine but not by 
alanine, indicating that the internalization signal was independent from phosphorylation events. In 
sum, RL13 binds human IgG and may contribute to HCMV immune evasion in the infected host, 
but this function does not readily explain the instability of the RL13 gene during viral propagation 
in cultured cells.  
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INTRODUCTION 
Human cytomegalovirus (HCMV) infection is common and, although typically subclinical in 
the healthy population, it can cause severe disease in congenitally infected infants and in individuals 
with suppressed immunity [1]. In immunocompetent individuals, infection is controlled by both 
cellular and humoral immune responses, defenses that are weakened in immunocompromised 
patients leading to infection of several tissues and a vast range of cell types [2]. 
Characterization and use of clinical and low passage isolates of cultured HCMV strains have 
led to a reconsideration of the viral coding potential and suggested the presence of new unidentified 
functions (reviewed in [3]). Comparative sequencing analysis of unpassaged clinical isolates versus 
cell culture adapted viruses allowed a more refined identification of the genetic changes 
corresponding to functions that are lost in in vitro cultures. This is the case of RL13 and UL128 
gene products, both possessing a suppressive phenotype on tissue culture adapted viruses [4,5]. For 
RL13 in particular, Stanton et al. recently reported rapidly emerging genetic mutations following a 
few passages of BAC-derived Merlin strain virus in cultures of human cells of different origins [6]. 
These authors, using an elegant BAC system of conditional gene repression during virus 
propagation, were able to show that virus with reconstructed wild type RL13 repressed cell culture 
growth while the emerging deletion mutants allowed the virus to adapt to cell culture growth [6]. 
Providing that a functional RL13 gene appears to be carried by all sequenced clinical isolates, the 
authors hypothesized that this protein is critical for productive HCMV replication in vivo, perhaps 
increasing the repertoire of HCMV cell tropism [6].  
HCMV has evolved a number of different ways to evade the immune system, often employing 
seemingly redundant factors and mechanisms to maintain the lifelong infection of the host [7]. 
Limitation of the host antibodies and complement activities through the expression of viral proteins 
able to bind the constant region of immunoglobulin G (Fcγ) is a mechanism common to several 
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herpesviruses [8,9]. These viral proteins interfere with the host receptors for the Fc portion (FcγRs) 
of immunoglobulin G (IgG), expressed on the surface of all cell types in the innate and adaptive 
parts of the immune system [10]. 
FcγRs are a complex family of proteins with several distinct classes and subclasses that 
function at the interface of the adaptive and innate immune systems [10]. They sense immune 
complexes in the extracellular environment and regulate signaling cascades in effector cells, which 
may contribute significantly to balancing pro- and anti-inflammatory responses to infection. HCMV 
expresses two proteins of 34 and 68 kDa that bind the Fc region of IgGs [11–13]. gp34 is encoded 
in clinical isolates by RL11 and in laboratory isolates by the duplicate genes TRL11 and IRL11 
[12,14]. gp68 is translated from the spliced mRNA encoded by UL119 and UL118 [11] and has 
been detected in preparations of purified virions [15]. Both gp34 and gp68 are glycosylated type I 
membrane proteins predicted to form immunoglobulin supergene family (IgSF)-like domains [11]. 
They bind all classes of human IgG with approximately equal affinity, whereas gp34 also binds 
rabbit IgG and, to a lesser extent, rat IgG1. 
In this report we identified two additional Fcγ binding activities encoded by the HCMV 
genome, RL12 and RL13, and characterized this property of recombinant RL13 from the TR and 
Merlin strains of HCMV. We demonstrated that RL13 transfected into cultured human epithelial 
and fibroblast cells binds and internalizes the Fc portion of human IgGs.   
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RESULTS 
Fcγ binding ability of selected members of the RL11 family 
RL11 was the first identified Fcγ binding protein of HCMV [12] and is hypothesized to 
function through its Ig-like domain [11]. Using RL11 as positive control, we sought to test if RL10, 
RL12 and RL13 were also able to bind human IgGs. We included gB (UL55) as a negative control. 
HEK293T cells were transfected with expression plasmids for myc-His tagged gB, RL10, RL11, 
RL12, RL13. 48 h after transfection, flow cytometry analysis was performed with DyLight 649-
conjugated human Fcγ and FITC-conjugated anti-myc. Permeabilized (Fig. 1A) and non-
permeabilized (Fig. 1B) FITC-positive cells were tested for ability to bind human Fcγ. RL11, RL12 
and RL13 bind the Fc portion of human IgG while RL10 and gB are comparable to negative control 
(Fig. 1A and 1B). It appears that a large fraction of the Fcγ-binding activity of RL13 (brown trace) 
is surface exposed, whereas a large fraction of RL11 and RL12 (blue and green trace, respectively) 
is not (Fig. 1A and 1B). Expression of the different proteins was equal as demonstrated by 
comparable percentage of FITC positive populations and their mean fluorescence intensity (data not 
shown). Taken together, these data suggested that RL12 and RL13 are two previously unidentified 
human Fcγ binding proteins encoded by HCMV.  
RL11 has been shown to bind all different subclasses of human IgGs [11]. To assess if RL12 
and RL13 differentially recognized human IgG subclasses, flow cytometry on permeabilized 
HEK293T cells expressing RL11, RL12, or RL13 was performed using individual human IgG 
subclasses as probes. Cells expressing RL11 bind all IgG subclasses whereas cells expressing RL13 
appear to specifically bind IgG1 and IgG2 (Fig. 1C).  
 
Chapter 4 
60 
 
These data and similar analysis of RL12 binding to human Ig isotypes and binding of RL12 and 
RL13 to Igs from different species are summarized in Table 1. Although the finding that RL12 
binds Fcγ was novel, we focused the rest of this report on RL13.  
 
 
 
 
Figure 1: FACS analysis of Fcγ and IgG binding. 
A: Binding of Fcγ to RL13 in permeabilized cells. HEK293T cells transfected with empty vector or 
expression vectors for myc-tagged gB, RL10, RL11, RL12 or RL13 were fixed, permeabilized and 
stained using FITC-conjugated anti-myc and 25 µg/ml DyLight 649-conjugated human IgG Fc 
fragment (Fcγ). FITC positive cells were compared to mock transfected cells for their ability to bind 
Fcγ.  
B: Binding of Fcγ to surface-exposed RL13. HEK293T cells transfected with empty vector or 
expression vectors for myc-tagged gB, RL10, RL11, RL12 or RL13 were first stained at 4°C with 
DyLight 649-conjugated human IgG Fc fragment (25 µg/ml). Excess of probe was removed by 
washing in PBS and then cells were fixed and stained with FITC-conjugated anti-myc. FITC 
positive cells were compared to mock transfected cells for their ability to bind Fcγ.  
C: Binding specificity of RL10-RL13 towards different human immunoglobulin subclasses. 
HEK293T cells were transiently transfected with myc-tagged RL11 (blue), RL12 (green), RL13 
(brown) or with empty vector (magenta). Cells were fixed, permeabilized and stained with FITC-
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conjugated anti-myc together with 10 µg/ml of human Ig of the different subclasses. Alexa fluor 
647-conjugated goat anti-human was used as secondary antibody. FITC positive cells were 
compared to mock transfected cells for their ability to bind Fcγ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Ig-binding specificity of Fc-binding proteins RL11, RL12 and RL13. 
HEK293T cells were transfected with expression plasmids encoding a tagged version of RL11 
RL12, and RL13 genes, stained with the indicated immunoglobulins, and analyzed by flow 
cytometry. +/++/+++ indicates efficiency of Fc-binding observed as mean fluorescent intensity; − 
indicates no binding. 
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Amino acid residues 109 to 218 of TR strain RL13 are necessary for Fcg binding 
The RL13 protein possesses strong topology similarities with the previously characterized HCMV 
Fcg binding proteins coded by the RL11 and UL119 genes (gp34 and gp68 respectively) [11]. 
HCMV RL13 is a member of the RL11 multigene family [16] encoding a characteristic domain, 
known as RL11D or CR1 [17]. RL13 from HCMV strain TR has the typical features of a type I 
membrane glycoprotein (Fig. 2A): a 20 amino acids (aa) long signal peptide, a transmembrane 
domain in the 248-268 aa region, and a predicted cytoplasmic tail of 26 aa in accordance with 
previous studies [6]. Further analysis suggests the likely presence of 11 N-linked glycosylation sites 
(pos. 21, 32, 37, 41, 90, 108, 120, 167, 201, 208, 215 aa) and 22 O-linked glycosylation sites along 
the sequence, all restricted to the N-terminal region between residues 40 and 89. gp34 and gp68 
contain a DxxxLL dileucine consensus motif for internalization and a potential I/V/L/SxYxxL 
intracytoplasmic immunoreceptor tyrosine based-like inhibition motif, respectively [11,12]. 
Similarly, we noted the presence of a tyrosine-based motif (YxxL) for intracellular targeting of 
transmembrane proteins [18] in the C-terminal cytoplasmic domain of the RL13 sequence (Fig. 2A). 
A search for conserved patterns in the TR RL13 ectodomain revealed an immunoglobulin (Ig)-like 
domain (Fig. 2A) identified as SM00409 (IG) in the SMART family classification (106-205 aa, 
with an HMMSmart E-value of 6.16e-04) [19]. A multiple sequence alignment generated from 15 
different HCMV strains reported a very high conservation along the entire domain except 3 short 
regions predicted to form loops (Fig. 2B). All 15 sequence variants contain an immunoglobulin 
domain identified as SMART SM00409 or Interpro IPR013783 (E-values ranging from 9.9e-07 to 
3.4e-04 and from 4.70E-07 to 6.10E-04, respectively). The secondary structure predictions 
suggested a propensity of the identified TR RL13 Ig-like domain to form a series of 8 beta-strands 
(Fig. 2B).  
Chapter 4 
64 
 
To investigate the involvement of the Ig-like domain in the Fcg binding ability, we produced 4 
different mutants of the RL13 ectodomain (Fig. 2C): RL13ΔNT, lacking 76 residues (aa 24-99) 
from the N-terminal region predicted to contain the O-linked glycosylation sites; RL13ΔE1, lacking 
29 (aa 218-246) residues between the Ig-like domain and the transmembrane region; RL13ΔE2 (aa 
159-246), with the same deletion as above plus 57 residues of the C-terminus of the Ig-like domain; 
and RL13ΔIg, lacking the entire Ig-like domain (aa 109-218). The mutant proteins were transiently 
expressed fused to myc and His tags in HEK293T cells with comparable expression levels as 
judged by flow cytometry analysis using anti-myc antibody (data not shown). 
Fcg binding ability was assayed by flow cytometry of myc-expressing permeabilized cells after 
staining with different concentrations of DyLight 649-conjugated Fcg (Fig. 3A, only 12.5 μg/ml 
concentration is shown). Quantification of the results is reported as percentage of Fcg stained cells 
in each sample compared to wild type RL13 (Fig. 3B). Values from RL13ΔNT were comparable to 
the wild type RL13, while a substantial reduction was observed in the RL13ΔE1 and RL13ΔE2 
samples. Deletion of the Ig-like domain carried by the RL13ΔIg (RL13ΔE1 and RL13ΔE2) mutants 
completely abolished specific Fcg binding since the number of positive cells was comparable to 
negative controls, cells expressing RL10 or transfected with empty vector (Fig. 3A-B).  
These data indicated that the Fcg binding activity of RL13 maps to amino acids 109-218. 
Removal of the region located between the Ig-like domain and the transmembrane domain severely 
impaired Fcg binding but did not completely abrogate it. This observation suggests that this region 
could be important for the stability of the binding and/or the correct protein fold. 
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Figure 2: Predicted structure of the RL13 protein and schematic representation of TR RL13 
ectodomain mutants.  
A: Schematic representation of the HCMV TR RL13 full length protein. The signal peptide at the 
N-terminus (SP), the Ig-like domain, the transmembrane domain (Tm), the tyrosine-based motif 
YxxL (Ym) sorting signal, 11 potential N-linked glycosylation sites (diamonds), and the O-linked 
glycosylation region (closed circles) are indicated. 
B: Multiple sequence alignment of the predicted RL13 Ig-like domain from the indicated strains of 
HCMV. The residues are colored according to the conservation level (red for higher conservation). 
Asterisks (*) below the alignments represent conserved amino acid in all sequences; colons (:) 
represent residues with similar physicochemical properties; dots (.) semi-conserved residues. The 
black arrows represent the positions of predicted β strands along the sequence.  
C: Graphic representation of TR RL13 and the ectodomain mutants used in this study. The amino-
terminal signal peptide, the carboxy-terminal transmembrane (gray boxes) and the Ig-like domain 
(white box) are indicated. 
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Figure 3: Fcγ-binding by RL13 ectodomain mutants.  
A: Cytofluorometric analysis of Fcγ binding by RL13 ectodomain mutants. HEK293T cells 
transfected with the indicated constructs were permeabilized and stained with DyLight 649-
conjugated human IgG Fc fragment (Fcγ, 12.5 μg/ml) and Alexa Fluor 488-conjugated mouse anti-
myc. Signals from 10,000 myc-positive cells are shown in each graph. The percentage of cells in 
each quadrant is indicated.  
B: Quantitative analysis of the FACS data. Each histogram shows the percentage of Fcγ positive 
cells relative to the RL13 wild type positive population (RL13). Values and error bars represent the 
mean and range of three independent experiments.   
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Subcellular localization of RL13 in transfected cells 
Stanton et al. recently reported that adenovirus-expressed RL13 transits through the Golgi and 
traffics mainly to Rab5-positive cytoplasmic vesicles [6]. We sought to verify the intracellular 
localization of RL13 expressed transiently in human cells. Confocal microscopy images were 
collected from epithelial (ARPE-19) and fibroblast (MRC-5) cells transfected with two different 
constructs, the previously described myc-His tagged construct and a second construct coding for 
RL13 with a C-terminal YFP-tag. Since sub-cellular localization of RL13 with different tags was 
identical in both cell types (data not shown), only representative data obtained in ARPE-19 human 
epithelial cells with RL13-YFP are shown. 
48 h after transfection, cells were fixed, permeabilized and stained with different markers of 
cellular compartments and with fluorophore-conjugated Fcγ. The confocal microscopy analysis of 
these samples is shown in Fig. 4A. RL13 co-localized to a limited extent with Golgi markers and 
EEA1-positive endosomes and more extensively with markers of the trans-Golgi network (TGN) 
(Fig. 4A, left panels). Fcγ co-localized extensively with RL13 (Fig. 4A, far right panels), although a 
population of RL13 that does not bind to the Fc of human IgGs was consistently observed (Fig. 4A, 
green color in far right panels). Although it is tempting to speculate that this pool represents an 
immature ER population, also suggested by the shape of the RL13 distribution, we have been 
unable to find any co-localization of RL13 with the ER marker PDI (not shown).  
The presence of RL13 on the surface of both HEK293T and ARPE-19 cells was further verified 
by the use of a mouse monoclonal antibody (mAb 5H3/B10) directed against the ectodomain 
portion of RL13. Analysis by flow cytometry was performed on transiently transfected non-
permeabilized HEK293T cells (Fig. 4B). A clear increase in fluorescence was obtained on RL13 
expressing cells stained with mAb 5H3/B10 compared to mock transfected cells or isotype control. 
Confocal microscopy analysis of non-permeabilized RL13 expressing ARPE-19 cells stained with 
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both Fcγ and 5H3/B10 revealed a strong accumulation of RL13 on plasma membrane clusters (Fig. 
4C) that extensively overlapped with Fcγ signals (Fig. 4C, white color in right merge panel).  
These observations are consistent with RL13 trafficking through the secretory pathway and 
recycling from the plasma membrane, although other possible explanations for this pattern have not 
been excluded.  
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Figure 4: Localization of RL13 in transfected cells. 
A: Co-localization of RL13 with organelle markers and Fcγ in ARPE-19 cells. ARPE-19 
epithelial cells were transfected with RL13-YFP fusion protein (green color, central column) and 
treated for confocal analysis 48 h later. Cells were fixed, permeabilized and stained with antibodies 
against either GM130, TGN46 or EEA1 intracellular markers (red color, second column) and with 
20 μg/ml of DyLight 649-conjugated human IgG Fc fragment (magenta color, fourth column). The 
merged panels on the far left show co-localization between RL13 and, from top to bottom, markers 
of Golgi (GM130), trans-Golgi (TGN46) and early endosomes (EEA1) respectively (co-localization 
in yellow). The merged panels on the far right show co-localization of Fcγ with RL13 (co-
localization in white). 
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B: Flow cytometry analysis of RL13 surface-expression. HEK293T cells were transiently 
transfected with vector coding for YFP (green line) or RL13-YFP fusion protein (red and blue 
lines). Cells were allowed to recover for 48 h and then surface-exposed RL13 was stained either 
with 5 μg/ml of mouse monoclonal antibody directed against RL13 ectodomain (clone 5H3/B10, 
red and green lines) or isotype control at the same concentration (isotype, blue line) on ice. Alexa 
fluor 647 conjugated goat anti-mouse was used as secondary antibody. YFP positive cells were 
compared to empty vector transfected cells for their ability to bind 5H3/B10 antibody. 
C: Immunofluorescence analysis of RL13 surface expression on ARPE-19 cells. ARPE-19 cells 
expressing RL13-YFP fusion protein (red color) were stained on ice with 12.5 μg/ml of 5H3/B10 
monoclonal antibody (green color) and 20 μg/ml of DyLight 649-conjugated human IgG Fc 
fragment (magenta color) without permeabilization. Merge panels show co-localization between 
5H3/B10 and either RL13-YFP or Fcγ signals (yellow color in the far left panel and white color in 
the far right panel, respectively).  
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Internalization of RL13-Fcγ complex 
The presence of an internalization motif in the C-terminal tail, together with the intracellular 
localization data in Fig. 4, suggested that RL13 could traffic to the cell surface where it may bind 
and internalize extracellular IgGs. To test this hypothesis, we performed a short time-course 
characterization of the internalization of YFP-tagged RL13 in transfected ARPE-19 cells. Cells 
were initially placed on ice to reduce lateral diffusion of membrane proteins and block potential 
internalization of the ligand. Fluorescently labelled Fcγ was added and allowed to bind for 30 min 
on ice. Following extensive washing of the Fcγ excess and fixation of the cells, fluorescence 
analysis at time 0 showed that RL13 partially co-localized with Fcγ on the surface of transfected 
cells (Fig. 5A). Restoring the internalization processes at 37°C induced the uptake of the RL13- Fcγ 
complex, the majority of which accumulated mostly in large ring-shaped structures after 30 min 
(Fig. 5B). These RL13-Fcγ structures persisted 90 min after the shift to 37°C and stained positive 
for the early endosome marker Rab5 (Fig. 5C). 
These data demonstrate that RL13 binds to the Fc of human IgGs on the cell surface and that the 
internalized complex remains associated with large membranous vesicles containing markers of 
early endosomes. 
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Figure 5: RL13 binds and internalizes Fcγ.  
ARPE-19 epithelial cells were transfected with RL13-YFP (green) and allowed to recover for 48 h. 
Cells were placed on ice 5 min before adding DyLight 649-conjugated human IgG Fc fragment 
(red) and incubated on ice for 30 min. Then, cells were washed and A: immediately fixed, B: 
shifted to 37°C for 30 min, or C: shifted to 37°C for 90 min before proceeding to fixation and 
confocal analysis. Rab5 (purple) was revealed by specific antibodies after permeabilization of the 
samples. Examples of co-localization between signals are indicated by white arrows. Orthogonal 
projections of the optical sections acquired from Z-stack are shown. White arrows indicate 
examples of co-localized spots. Fluorescent Fcγ was absent on the membrane of ARPE-19 cells 
transfected with empty expression vector used as control and no staining was detected following 30 
min switch at 37°C (data not shown).   
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Mutation of RL13 sorting motif affects the internalization of Fcγ 
As shown by the in silico analysis, the carboxy-terminal domain of RL13 contains a tyrosine-based 
sorting signal (YxxL282) that could be responsible for the internalization of the RL13-Fcγ complex. 
A local multiple sequence alignment of the C-terminal region of RL13 from 15 HCMV strains 
showed that the YxxL motif was highly conserved (Fig. 6A, residues 279-282). To test the 
contribution of the cytoplasmic tail, and in particular of the tyrosine motif, to the internalization of 
the RL13-Fcγ complex, a panel of mutants were built (Fig. 6B). Plasmids encoding RL13 with three 
single amino acid substitution mutants, Y279F, Y279A, T280A, one double substitution mutant 
Y279A/L282A (indicated as AA), one triple substitution mutant Y279A/R281A/L282A (AAA), 
and one quadruple substitution mutant with all amino acids of the motif replaced by alanines 
(AAAA) were produced. Additionally, plasmids encoding a YxxL deletion mutant (Δ279-282), a 
deletion of the motif and the entire C-terminal (Δ279-294), and a deletion of 12 amino acids 
immediately C-terminal to the sorting motif (Δ283-294) were generated. 48 h after transfection, 
internalization of the mutated/deleted proteins was assessed by flow cytometry on HEK293T cells 
incubated with Fcγ at 4°C for 30 min and, after removal of the ligand by extensive washing, shifted 
to 37°C. The percent of internalized Fcγ was calculated from the mean fluorescence intensity of the 
samples incubated at 37°C for 30 minutes and the samples submitted to the same treatment but kept 
on ice. As shown in Fig. 6C, the YxxL motif is critical for protein internalization since removing 
the region downstream did not alter the RL13 Fcγ internalization ability while deletion of the motif, 
both individually or with the C-terminus sequence, strongly reduced the internalization ability of 
RL13 (Fig. 6C). Substitution of the tyrosine 279 with phenylalanine, an alternative aromatic side 
chain, did not reduce the ability of RL13 to internalize. In contrast, uptake was reduced by 
approximately 1/3 when an alanine was placed in this position. Substitution of the adjacent 
threonine 280 with alanine did not show a difference in internalization compared to the wild type. 
However, leucine 282 appeared to play a role as shown by the further internalization reduction of 
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the Y279/L282 double mutant (Fig. 6C). Substitution of multiple residues with alanine reduced 
internalization to the same extent as complete deletion of the YxxL motif (Fig. 6C).  
Taken together these results are consistent with the YxxL282 motif being necessary for Fcγ 
internalization by RL13 and suggest that an aromatic residue at position 279 is required.  
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Figure 6: RL13 C-terminal YxxL motif is required for internalization. 
A: Local multiple sequence alignment of the RL13 C-terminus. The gray box indicates the 
transmembrane domain, the black box the YxxL internalization motif. Darker color indicates higher 
conservation. Asterisks (*) below the alignments represent conserved amino acid in all sequences; 
colons (:) represent residues with similar physicochemical properties; dots (.) semi-conserved 
residues.  
B: Graphical representation of RL13 mutations used in this study. RL13 TR cytoplasmic tail 
sequence is shown with mutated amino acids in bold. Amino acids unchanged from the wild-type 
sequence are represented by a dot. Deleted amino acids are represented by a |. 
C: Internalization efficiency of RL13 variants. HEK293T cells were transfected with the 
indicated plasmids coding for wild type and mutated RL13. 48 h post-transfection, cells were 
detached and incubated on ice for 60 min with human Fcg fragment. Cells were then washed and 
incubated in medium at 37°C for 30 min to allow for endocytosis (T37). The control sample 
remained on ice (T0). Following incubation, cells were cooled quickly by rinsing twice with cold 
PBS; Fcg that remained on the cell surface after endocytosis was stained with Alexa Fluor 647-
conjugated goat anti-human IgG and analyzed by flow cytometry. The % of internalization was 
calculated from the mean fluorescence intensities of transfected cells with the following formula: 
(T0−T37)/T0×100%. Value retrieved from RL13 wild type was set to 100%. Values are the mean 
and range of three independent experiments. Significant differences, P<0,001 (two-tailed unpaired 
Student’s t-test), compared to RL13 are indicated by *.  
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Fcγ binding ability is conserved in the HCMV Merlin strain 
Due to the high variability of the RL13 genes among different HCMV strains [20] we also tested the 
Merlin RL13 protein (87% aa identity with its TR counterpart) for its Fcγ binding ability. In vitro 
synthesized Merlin RL13 gene was cloned in pcDNA3.1(-)/myc-His expression vector and used to 
transfect HEK293T cells. Intracellular staining was performed as previously described and cells 
were analyzed through flow cytometry. Both the expression levels (data not shown) and the Fcγ 
binding ability of cells expressing RL13 from Merlin and TR strains were comparable (Fig. 7A). To 
further confirm the specificity of the binding, both proteins were immunoprecipitated from 
transfected cell lysates with biotinylated Fcγ. Complexes were captured with magnetic streptavidin 
beads and eluted material was separated by SDS-PAGE and analyzed by immunoblot using anti-tag 
and anti-human IgG antibodies (Fig. 7B). Both Merlin and TR RL13 proteins were successfully 
immunoprecipitated from cell lysates. The observed molecular weights of the two proteins in 
denaturing and reducing conditions appeared to be slightly different: TR RL13 was composed of 
three major isoforms of around 123 kDa, 111 kDa and 76 to 66 kDa, while Merlin RL13 gave three 
bands of 116 kDa, 108 kDa and 66 to 52 kDa. These differences in the molecular weight could 
reflect the different glycosylation profiles, with 7 and 11 predicted N-linked glycosylations for 
RL13 from Merlin and TR strains, respectively.  
These experiments support the conclusion that the Fcg-binding ability of RL13 is conserved in 
at least two different clinical HCMV isolates. 
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Figure 7: Fcg binding is a conserved function for recombinant RL13 from Merlin and TR 
clinical strains. 
A: HEK293T cells were transfected with plasmids coding for myc-His tagged RL13 from TR (red), 
Merlin (blue) strains and empty vector (green). 48 h post-transfection cells were collected, 
permeabilized and stained with FITC-conjugated mouse anti-myc and 25 μg/ml of DyLight 649-
conjugated human IgG Fc fragment. 10,000 FITC-positive cells were compared to empty vector 
transfected cells.  
B: HEK293T cells were transfected with empty vector or plasmids coding for myc-His tagged 
RL13 from TR and Merlin strains. 48 h post-transfection cells were collected, lysed and subjected 
to immunoprecipitation with biotinylated Fcg fragment. Total lysates and elution fractions were 
subjected to western blot analysis using HRP-conjugated anti-his tag (α-his) and anti-human IgG 
(α-h) antibodies. TR: sample expressing myc-His tagged RL13 from TR strain; Merlin: sample 
expressing myc-His tagged RL13 from Merlin strain; Empty: empty vector transfected cells. 
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DISCUSSION 
The low fitness of wild-type RL13-carrying strains cultured in vitro, leading to the destruction 
of the ORF present in the clinical isolates within a few passages [5,6], make functional studies of 
this protein difficult. To better understand its function, we used synthetic RL13 genes reproducing 
the sequences of the clinical isolates TR and Merlin. In the absence of an unpassaged reference 
sample of TR, we cannot say with certainty that the sequence and function of the TR RL13 we used 
is identical to the originally isolated, naturally occurring virus. However, we do not detect 
functional differences between RL13 from the TR and Merlin strains. Expression of this 
recombinant protein in human-derived epithelial cells allowed us to demonstrate that RL13: a) 
binds Fc from IgG of human (and rabbit) origin; b) preferentially binds to Fc from IgG1 and IgG2 
subclasses; c) is at least transiently exposed on the cell surface and is subsequently internalized with 
(and likely without) bound Fcγ; d) internalization relies on a YxxL motif and e) its Ig-like 
extracellular domain is necessary for Fcγ binding. Similar analysis of RL13 in human fibroblasts 
produced identical results (data not shown). Furthermore, we revealed that RL12 also binds IgG1 
and IgG2, although we did not study this interaction in detail. Our data does not offer an 
explanation for why RL13 is so rapidly mutated when clinical isolates of HCMV are grown in 
cultured cells [5].  
Apart from HCMV, viral Fcγ binding proteins (vFcBPs) are present on herpes simplex virus 
type 1 (HSV-1), HSV-2, and varicella zoster virus and on the non-human herpesviruses 
pseudorabies virus and murine cytomegalovirus [21–25]. The most accepted model to explain how 
those activities promote immune evasion is the so called “antibody bipolar bridging” in which the 
neutralizing potential of the IgG Fab domain is counteracted by simultaneous binding of vFcBPs to 
the Fc domain of the same immunoglobulin molecule [26,27]. The possibility of this mechanism 
has been supported at a molecular level by Sprague and coworkers [27], who crystallized a portion 
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of HSV gE ectodomain and gE-gI complex bound to an human IgG Fc fragment. Alternatively, it 
has been hypothesized that HSV, as well as HCMV vFcBPs, function once expressed on infected 
cell surface by endocytosis and subsequent degradation of complexes including human IgG and 
viral antigens [11,27]. Consistent with this hypothesis, we observed that RL13 is able to internalize 
human IgG Fc fragment from the surface of transfected cells trafficking at early times in Rab5 and 
EEA1 positive endosomes. The well-recognized YxxL motif is essential for RL13 endocytosis 
through the aromatic nature of the tyrosine and not its property of phosphate acceptor. As already 
described for the RID receptor of adenovirus [28], this type of sorting signal does not affect signal 
transduction pathways. On the other hand, the fact that RL13 is located on the envelope of the virus 
[6] suggests that antibody bipolar bridging could be an important function of RL13 that would help 
protect HCMV virions from complement- and antibody-dependent neutralization.  
RL13 and RL12 discriminate among human IgG subtypes showing no association with IgG3 
and IgG4. To our knowledge, this observation remains the only example of vFcBPs selecting not 
only among immunoglobulin isotypes but also IgG subtypes. IgG2 represents roughly 25% of 
human total plasma IgGs in adults and has been traditionally associated with protection from 
infection with encapsulated bacteria since their immune function is primarily directed against 
polysaccharide antigens [29]. Recent reports, however, have pointed out a significant association 
between IgG2 deficiency and severe or even fatal clinical outcome of the pandemic influenza A 
(H1N1), although IgG2 unbalance has been suggested to be a consequence of cytokine deregulation 
rather than a predisposing risk factor [30,31]. Due to the low number of studies performed on 
human IgG2 function related to viral infection, the meaning of such observation remains elusive 
and needs further analysis. Compared to IgG1, subtype 2 immunoglobulins cannot mediate 
complement-dependent cytotoxicity or NK-mediated antibody-dependent cellular cytotoxicity 
(ADCC) but do engage FcγRIIa receptors and trigger ADCC mediated by cells of the myeloid 
lineage [32] (9) (Schneider-Merck, Lammerts van Bueren et al. 2010). Again, the relative 
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importance of IgG2 subtype in protecting from viral infection just begun to be addressed and it is 
difficult to evaluate the importance of a viral factor able to counteract such mechanism, if any, but it 
is noteworthy that HCMV has a latent reservoir in myeloid cells [33]. It is tempting to speculate that 
a viral IgG2-binding receptor could compete with cellular receptors for binding to cellular 
antibodies to viral proteins and prevent ADCC. It would be important to determine the affinity of 
RL13, as well as of the other HCMV Fcγ binding proteins, toward IgG2 to evaluate if this protein 
represents a function more dedicated to a particular IgG subtype.  
Atalay and coworkers described the presence of immunoglobulin supergene family (IgSF)-like 
domains in the products of both RL11 and UL119 genes [11]. We have mapped the RL13 Fcγ 
binding activity to the Ig-like domain in the extracellular region, while the N-terminal proximal 
region composed of approximately 70 amino acids is not crucial for the binding. Indeed, Sprague et 
al. showed that removing the N-terminal part of the gp68 ectodomain did not impair the Fcg binding 
[13] (10) (Sprague, Reinhard et al. 2008). These data are consistent with the presence of an 
immunoglobulin supergene family (IgSF)-like domains in all the described HCMV Fc binding 
proteins. Our findings do not rule out the possibility that RL13 could carry out other functions. The 
best characterized viral Fc binding protein, the gE product of HSV-1, is also involved in cell-to-cell 
spread or trafficking of viral proteins from neuron body cell into axon independently of its Fc 
binding capability [34,35]. We are currently investigating other possible roles of RL13 during 
HCMV pathogenesis.  
Our preliminary characterization of transiently transfected RL13 agrees only partially with what 
was reported by Stanton et al. [6]. They found significant differences in cellular localization and 
apparent SDS-PAGE MW between adenovirus-expressed RL13 and the protein expressed in the 
context of viral infection. In their report, adenovirus-expressed RL13 showed a lower MW (80 and 
55 kDa) compared to the species found in infected cells (100 and 55 kDa) and the protein only co-
localized with TGN in the context of infection [6]. The behavior of RL13 observed in this report is 
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more similar to Stanton et al.’s data for infected cells, showing a MW above 100 kDa and a sub-
cellular co-localization with early endosomes and the TGN. This last observation would be 
consistent with a default mechanism of internalization similar to what was described for other 
HCMV envelope proteins [36]. We currently have no explanation for the slight discrepancies 
between Stanton et al. and our report that may be due to the different expression system used or, at 
least for the confocal analysis, to the protein derived from a different strain. However, 
characterization of the expressed RL13 remains preliminary and further studies will elucidate this 
point. 
To conclude, we have shown that RL13 encoded by HCMV TR binds the Fc portion of human 
IgG1 and IgG2 and propose that this protein is used by the virus to circumvent the humoral immune 
response in the host.  
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MATERIALS & METHODS 
Sequence data, in silico analysis and predictions 
Start to stop open reading frames (ORFs) in the complete genome sequence of the TR strain 
(Genbank: AC146906.1) were identified using the Getorf program from the EMBOSS suite 5.0.0 
[37]. The sequence similarity searching algorithm FASTA 35.4.3 [38]. was exploited to compare the 
protein sequences of RL13 gene product from the Merlin strain (Genbank: YP_081461.1) to all the 
TR ORFs and select homologous ones with BLOSUM50 as substitution matrix and imposing an 
expectation value (E) upper limit of 1e-05. The putative TR RL13 sequence was searched for 
specific conserved signatures using InterProScan 4.8 [39] with databases v.34.0. Multiple sequence 
alignments were performed using the PSI-Coffee mode of T-Coffee v.9.01 [40], comparing the TR 
RL13 with an additional 14 different RL13 protein sequences (Genbank: YP_081461.1, 
AEI84615.1, ACS91939.1, AAR31271.1, AAR31220.1, ACT81850.1, ACT81685.1, ACS92104.1, 
ACZ79760.1, ACZ79925.1, ADI46773.1, ACZ80255.1, ABV71530.1, ACZ80090.1). Signal 
peptides and transmembrane regions were predicted by Phobius [41], while secondary structures 
were predicted using PSIPRED [42]. N-linked and O-linked glycosylation sites were predicted 
using NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/) and NetOGlyc 3.1 [43] 
(http://www.cbs.dtu.dk/services/NetOGlyc/) respectively. 
Cells, plasmids and antibodies 
ARPE-19, MRC-5 and HEK293T cell lines were brought from ATCC and cultured according to 
the supplier’s instructions. DMEM high glucose and DMEM:F12 media (Gibco, Invitrogen) were 
supplemented with 10% fetal calf serum (FCS) and penicillin streptomycin glutamine (Gibco, 
Invitrogen). Lipofectamine 2000 (Invitrogen) was used to transfect HEK293T cells while Fugene 6 
(Roche) and Nucleofector kit V (Amaxa) were used to transfect ARPE-19 cells as suggested by 
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manufacturer. Human codon-optimized RL10, RL11, RL12, RL13 and gB (UL55) HCMV genes 
based on the TR strain sequence and RL13 from Merlin strain (NCBI Reference Sequence: 
YP_081461.1) were synthesized by Geneart and cloned in plasmid pcDNA3.1(-)/myc-His C 
(Invitrogen) in frame with C-terminal myc and six histidine tag sequences. Fluorescent fusion 
proteins were obtained by subcloning a gene of interest upstream of the EYFP sequence in pEYFP-
N1 vector (Clontech). Ectodomain and C-terminal tail RL13 mutants were cloned using 
QuickChange™ Site-directed Mutagenesis kit and instructions therein (Stratagene). Primary 
antibodies used in this work were mouse anti-His (C-term) and mouse anti-PDI (Invitrogen), mouse 
anti-Rab5 mouse, anti-GM130, mouse anti-TGN46 and mouse anti-EEA1 (Abcam). Mouse 
monoclonal antibody against RL13, clone 5H3/B10, was developed by Areta International 
(Gerenzano, Italy). Mice immunization was performed with peptides encompassing the amino acid 
region 111-246 of TR strain RL13. Secondary antibodies were Alexa Fluor 488-, 568-, and 647-
conjugated goat anti-mouse (Invitrogen) and HRP-conjugated secondary antibodies from Perkin 
Elmer. Chrompure DyLight 649-conjugated rat, rabbit, mouse, goat IgG and human Fc fragment 
were from Jackson Immunoresearch, human IgG subclasses from SIGMA, and human IgA, IgE, 
IgM from Calbiochem.  
Flow cytometry 
For intracellular staining, HEK293T cells transfected with the plasmids of interest were trypsin 
detached 48 h post-transfection, incubated 30 min at RT with Live&Dead Agua (Invitrogen), 
diluted 1:400 in PBS, fixed and permeabilized with Cytofix/Cytoperm kit (BD) and stained as 
instructed by the manufacturer. For cells expressing the myc-tagged proteins, mouse anti-myc-FITC 
antibody was used at 1:500 dilution. Binding of the Fc portion of the human IgGs (Fcγ) was 
assessed using DyLight 649-conjugated human IgG Fc fragment or different human 
immunoglobulin isotypes and human IgG subclasses at different concentrations (5-50 μg/ml). Alexa 
Fluor 647 fluorophore-conjugated secondary antibodies against the above mentioned species were 
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used at 1:200 dilution. For membrane staining, transfected cells were detached with trypsin 48 h 
post-transfection and incubated for 30 min on ice with DyLight 649-conjugated human Fcγ. When 
needed, cells were subsequently subjected to intracellular staining. A total of 10
4
 cells were 
analyzed for each histogram using FACSCanto II (Becton Dickinson, Heidelberg, Germany). For 
detection of membrane exposed RL13, HEK293T were transiently transfected with vectors coding 
for YFP or RL13-YFP fusion protein, were incubated with different dilutions of mouse monoclonal 
5H3/B10 antibody or mouse IgG1 isotype control (Sigma) for 60 min on ice. As secondary 
antibody, Alexa Fluor 647-conjugated goat anti-mouse was used for 30 min on ice at 1:200 dilution. 
Internalization of Fcγ in HEK293T cells was quantified through flow cytometry. 48 h post-
transfection cells were detached with trypsin and transferred to round bottom 96 well plates for 
staining. Cells were washed in cold PBS and incubated on ice with human IgG Fc fragment at 
different concentrations (50, 25, 12.5 μg/ml). After 30 min incubation, cells were extensively 
washed and incubated with warm medium to allow for endocytosis (Fcγ37°C). Half of the samples 
were kept on ice for the duration of the experiment (Fcγ4°C). At the end of the endocytosis, cells 
were washed with cold medium and Fcγ remaining on the surface was stained with Alexa fluor 488 
conjugated goat anti-human antibody. The percentage of internalized Fcγ was calculated as: (Fcγ4°C 
- Fcγ37°C)/Fcγ4°C x 100. Values shown are relative based on internalization by RL13 wild type. 
 
Confocal microscopy analysis 
Cells transfected with plasmids of interest were trypsin detached and plated on glass coverslips 
for 24 h post transfection. For intracellular staining, cells were fixed 48 h post transfection with 
3.7% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Sigma), blocked with PBS with 
1% BSA and stained at RT by incubating for 1 h with primary antibodies in PBS/1% BSA, washed 
in PBS, and further incubated with secondary antibodies in PBS/1% BSA for 1 h. The ProLong 
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Gold with DAPI (Invitrogen) was used as mounting solution. For membrane staining, the 
permeabilization step was omitted and fixation was performed after staining with primary and 
secondary antibodies for 30 min on ice. For human Fcγ internalization, cells expressing RL13-YFP, 
YFP, or empty vector (controls) were plated on glass coverslips 24h post transfection. 24 h later, 
cells were washed in cold PBS and incubated at 4°C with 20 μg/ml of DyLight 649-conjugated 
human Fcγ for 30 minutes. After extensive washes, temperature was switched to 37°C to allow for 
internalization. When required, cells were fixed, permeabilized and stained before mounting. The 
intracellular locations of antibody-tagged or fluorescent fusion proteins were examined under laser 
illumination in a Zeiss LMS 710 confocal microscope and images were captured using ZEN 
software (Carl Zeiss). 
 
Immunoprecipitation 
HEK293T cells were transfected with empty vector or myc-His tagged RL13 from TR or 
Merlin strains. 48 h post-transfection, cells were harvested, washed in cold PBS several times and 
lysed in lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% glycerol, 1 mM EDTA) 
containing 1% NP-40 (Roche) and supplemented with complete EDTA-free protease inhibitors 
(Roche). Supernatants were collected after centrifugation at max speed for 30 min at 4°C in a 
tabletop centrifuge. 100 µg of lysate was incubated with 2 μg of biotinylated human IgG Fc 
fragment (Jackson immunoresearch) for 1 h at 4°C, then with 30 μl of Streptavidin Dynabeads 
(Invitrogen) prewashed in lysis buffer. Precipitation was carried out at 4°C with overnight rotation. 
Immunocomplexes were collected using magnetic beads, washed 4 times with lysis buffer and 
eluted by adding 30 µl of LDS-buffer and heating at 96°C for 5 minutes. Lysates were mixed with 
100 mM DTT (Sigma) and heated at 96°C for 3 min. Proteins were then separated by SDS-PAGE 
and blotted on a nitrocellulose membrane. Membranes were blocked in blocking buffer (5% w/v 
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nonfat dry milk in PBS with 0.1% Tween 20). All incubations with antibodies were done at room 
temperature for 1 h in blocking buffer. Mouse anti-His (Invitrogen) was used at 1:1,000 dilution. 
Secondary antibodies were diluted 1:10,000 in blocking buffer.   
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